



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

EP00/08410

REC'D 14 NOV 2000

WIPO

PCT

Bescheinigung

Certificate

Attestation

4

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

00870145.0

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts:
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE

07/11/00





Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.
Application no.
Demande n° 00870145.0

Anmeldetag
Date of filing
Date de dépôt 27/06/00

Anmelder
Applicant(s)
Demandeur(s)
K.U. Leuven Research & Development
3000 Leuven
BELGIUM

Bezeichnung der Erfindung
Title of the invention
Titre de l'invention
Novel target for antifungals and inhibitors therefor

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat
State
Pays EP

Tag
Date
Date 30/08/99

Aktenzeichen
File no
Numéro de dépôt

EPA 99202805

Internationale Patentklassifikation
International Patent classification
Classification internationale des brevets

/

Am Anmeldetag benannte Vertragsstaaten
Contracting states designated at date of filing AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/TR
Etats contractants désignés lors du dépôt

Bemerkungen
Remarks
Remarques



NOVEL TARGET FOR ANTIFUNGALS AND INHIBITORS THEREFOR

The present invention relates to the use of an enzyme found in fungi, bacteria, insects, nematodes, worms, protozoa, mites and other organisms expressing that enzyme as a target in a screening assay by means of which agents capable of inhibiting the function of that enzyme may be identified. The screening assay may include complete cell or purified-enzyme assays adaptable for automation. In particular, the present invention relates to a screening assay for inhibitors or suppressors of sugar alcohol phosphatases or sugar phosphatases as well as preparations, in particular, pharmaceutical preparations, which include the inhibitor or suppressor obtained from the screening assay.

TECHNICAL BACKGROUND

Fungal cells and fungal spores have an amazing capacity for adaptation to survival under stress conditions and resume their vital functions as soon as the stress condition is removed. These organisms withstand freezing, strong vacuum, high doses of ionizing radiation, high pressure, osmotic stress and extreme temperatures without suffering damage and many of them accumulate the non-reducing disaccharide trehalose as a protein and membrane protectant.

The biosynthesis of trehalose consists of two enzymatic steps catalyzed by trehalose-6-phosphate synthase (TPS, expressed by the *TPS1* gene), which synthesizes trehalose-6-phosphate and by trehalose-6-phosphate phosphatase (TPP, expressed by the *TPS2* gene) which forms trehalose. Detailed information on the composition and function of the trehalose synthase complex can be found in Reinders A. et al. (Mol. Microbiol. 24, 687-695, 1997) and Bell W. et al. (J. Biol. Chem. 276, 33311-33319, 1998). In addition to its classical role in storage sugar accumulation, trehalose metabolism is known to play an important role in stress resistance, control of glucose influx into glycolysis and glucose-induced signaling.

As described in the article by De Virgilio et al., J.Biochem., vol. 212, 1993, pages 315-323, the disruption of the *TPS2* gene in *Saccharomyces cerevisiae* causes loss of trehalose-6-phosphatase activity and accumulation of trehalose-6-phosphate whereas the wild-type strain had hardly detectable levels of the trehalose-6-phosphate. It appears that accumulation of high levels of trehalose-6-phosphate is inhibitory to growth and survival, since conditions that lead to the accumulation of trehalose in wild-type cells cause loss of

viability of the *tps2* disruption mutant. This is observed for instance upon incubation at 37°C and when the cells are grown into stationary phase.

The incidence of fungal infections in patients has dramatically increased in the last 20 years (Klepser M. E. et al., Ann. Pharmacother., vol. 32, 1998, pages 1353 – 1361). Especially *Candida albicans* has become an important opportunistic pathogen. Patients suffering from immunodeficiency are especially vulnerable to infections with *Candida* and other fungi. Although *Candida albicans* is a common microorganism, found in the digestive tract and cavities of 10 to 50% of normal humans, upon a decreased resistance to infection in the host or upon administration of antibiotics for a long term or upon a surgical invasion, these microorganisms proliferate abnormally, damage tissues, and can enter the blood. Treatment is often hampered by the fact that many agents which are active against fungi also are toxic to mammalian cells, leading to a low therapeutic index and undesirable side effects in the patient.

A selection of drugs is available to combat fungal infections: Amphotericin B, Flucytosine, Ketoconazole, Miconazole, Fluconazole, and Itraconazole (Polak A., Progress in Drug Research, Vol. 49, 1997, pages 219-318). All these drugs have specific drawbacks. Amphotericin B is very efficacious because of its fungicidal action but is also relatively toxic to the patient especially to the renal functions. Flucytosine has a limited antifungal spectrum and the appearance of resistant cells is very frequent. As a result it is only used in combination with other drugs. Ketoconazole has a broad spectrum and is very useful for deep mycoses but it shows significant interactions with other drugs and causes endocrinopathies and hepatopathies. It cannot be used in immunosuppressed patients. Miconazole suffers from similar problems as Ketoconazole. Fluconazole and Itraconazole are more specific, less toxic and more efficacious than Ketoconazole and Miconazole. However Fluconazole is active against fewer fungi. Itraconazole is highly lipophilic and as a result reaches only low levels in most body fluids. As a result there is a requirement for novel antifungals with broader spectrum, higher efficacy and less side-effects.

The azole class of antifungals is also widely used in agriculture to combat plant pathogenic fungi (Adams D.J., 1997, In: Molecular genetics of drug resistance, eds. Hayes J. H., Wolf C. R., Harwood Academic Publishers, The Netherlands).

A common problem with all existing drugs is the appearance of resistance in the fungal pathogens. The longer the drugs are in use the more resistance is observed. This

requires the constant development of new antifungal drugs for which the pathogens still show great sensitivity.

The same problem applies to agriculture where a steady increase in resistance to antifungals is observed in many plant pathogenic fungi (Adams D. J., 1997, In Molecular genetics of drug resistance, eds. Hayes J. H., Wolf C. R., Harwood Academic Publishers , The Netherlands).

Some antifungal drug discovery efforts have been directed at components of the fungal cell or its metabolic pathways which are unique to fungi, and hence might be used as targets of new therapeutic agents. Ideally, these should act on the fungal pathogen without undue toxicity to host cells. Because no single approach is effective against all fungal pathogens and because of the possibility of developed resistance to previously effective antifungal compounds, there remains a need for new antifungal agents with novel mechanisms of action. An essential aspect of meeting this need is the selection of an appropriate component of fungal structure or metabolism as a therapeutic target.

Despite the increased use of rational drug design, a preferred method continues to be the mass screening of compound libraries for active agents by exposing cultures of pathogens to the test compounds and assaying for inhibition of growth. In testing thousands or tens of thousands of compounds, however, a correspondingly large number of fungal cultures must be grown over time periods which are relatively long. Moreover, a compound which is found to inhibit fungal growth in culture may be acting not on the desired target but on a different, less unique fungal component, with the result that the compound may act against host cells as well and thereby produce unacceptable side effects. Consequently, there is a need for assay or screening methods which more specifically identify those agents that are active against a certain intracellular target. Additionally, there is a need for assay methods having greater throughput, i.e., which reduce the time and materials needed to test each compound of interest.

It is an object of the present invention to provide a screening assay to identify pharmaceuticals with improved effectivity against fungal disease.

It is an object to provide a method of identifying useful antifungal drugs and coagents for antifungal drugs, which reduce the side effects of conventional drugs.

SUMMARY OF THE INVENTION

The present invention includes a novel target for antifungal agents, such as

antifungal drugs or fungicides, that is not required for growth of the fungus under standard conditions in vitro but that is specifically required for survival of the fungus under all conditions of reduced growth or absence of growth and all other conditions which in some way deviate from optimal growth conditions and/or apply stress to the
5 fungus.

In accordance with embodiments of the present invention trehalose-6-phosphate phosphatase and similar phosphatases converting sugar-, glycerol- and sugar alcohol phosphates to the corresponding unphosphorylated compounds as well as the genes expressing these enzymes are targets for antifungal agents, such as antifungal drugs or
10 fungicides, either alone or in combination with agents, e.g. drugs, inhibiting growth of the cells. Inhibition of the enzyme in fungal pathogens, either directly or by blocking its expression from the corresponding gene, leads to accumulation of trehalose-6-phosphate rather than trehalose, the cells will enter into a vicious circle of stress and enhanced synthesis to even hyperaccumulation of trehalose-6-phosphate as a reaction against the
15 stress, and they will rapidly die. Preferably, other parallel pathways to produce trehalose are inhibited so that the targeted cell has high trehalose phosphate levels and low trehalose levels thus doubly weakening the cell against attack by antifungal agents such as antifungal drugs or fungicides or by the immune system of the host.

The present invention includes inhibitors of trehalose-6-phosphate phosphatase.
20 Inhibition of this enzyme can lead to much faster elimination of the fungal pathogen. This effect might be obtained by such inhibitors alone or in combination with commonly known antifungal agents, e.g. antifungal drugs or fungicides.

The present invention is also applicable to other organisms that synthesize large quantities of trehalose, using this sequence of enzyme reactions, such as bacteria, insects,
25 nematodes, worms, mites, protozoa etc. The present invention includes all cellular parasites of mammals which depend on trehalose synthesis for survival, and which make use of trehalose-6-phosphate phosphatase as part of the trehalose biosynthesis pathway.

Non-optimal growth conditions generally prevail during growth of fungal pathogens in host organisms and under these conditions the target therefore is essential.
30 Trehalose-6-phosphate phosphatase, the second enzyme in the biosynthesis pathway of trehalose, converts trehalose-6-phosphate into trehalose. All fungi contain trehalose, which serves as a storage carbohydrate and as a stress protectant. Because of these functions trehalose is accumulated under unfavorable growth conditions and in survival

forms where it can reach very high concentrations. Trehalose-6-phosphate on the other hand is normally only found in very low concentrations and its accumulation at high levels is toxic to the cells. It is synthesized by trehalose-6-phosphate synthase, which is encoded by the *TPS1* gene. Inactivation of the *TPS2* gene, which encodes trehalose-6-phosphate phosphatase, renders fungal cells hypersensitive to stress conditions, for example, commonly used antifungals specifically under non-optimal growth conditions. As an example this is demonstrated for the fungus *Saccharomyces cerevisiae*. The genes of trehalose metabolism, including the *TPS2* gene, are also present in *Candida albicans*, an important human pathogen. Equivalent genes to, or names for *TPS2* are *HOG2*, *PFK3*, *D4416*, *YD8554.07*, *YDR074W*. In addition, all existing knowledge indicates that trehalose metabolism uses the same enzymes, trehalose-6-phosphate synthase and phosphatase, in all fungi, including fungal pathogens of humans, mammals and other animals, and plants. Under non-optimal growth conditions and a variety of stress conditions fungal cells, including those of pathogens such as *Candida albicans*, accumulate large quantities of trehalose and often also other sugars or polyols. Inhibitors of trehalose-6-phosphate phosphatase cause accumulation of trehalose-6-phosphate. Mutants deficient in the trehalose-6-phosphate phosphatase enzyme or cells treated with the novel inhibitors in accordance with the present invention accumulate large quantities of trehalose-6-phosphate under these conditions, which is highly toxic to the cells because it is a strong acid. It acts as a pleiotropic agent impairing a wide range of essential cellular components and cellular defense systems. Because the accumulation of trehalose-6-phosphate itself is a stress condition to the cell and because the trehalose-6-phosphate is synthesized as a reaction to the stress condition, the cells enter into a vicious circle after which they finally die. The present invention also includes all similar metabolic situations, such as the conversion of glycerol-3-phosphate to glycerol, mannitol-1-phosphate to mannitol, sorbitol-6-phosphate to sorbitol, arabitol-5-phosphate to arabitol, erythritol-4-phosphate to erythritol. Glycerol is generally accumulated in fungi under osmotic stress. Depending on the species sugar alcohols are accumulated together with trehalose. This is probably the case for instance in *Aspergillus fumigatus*.

It should be emphasized that a purpose of the antifungal agents in accordance with the present invention is not only to block the growth of the fungus but preferably to eradicate the fungus or to assist in its eradication. Hence, although it is useful to have an antifungal that blocks the growth of the fungus, it is much better to have an antifungal

that kills the fungus. Especially in immunocompromised hosts the difference between mere inhibition of growth of the fungus and actual killing of the fungus is important since these patients will have a reduced capacity to eliminate the fungus themselves when its growth is merely inhibited.

5 The synthesis of trehalose is induced in fungi under a variety of stress conditions. In yeast it is part of the general stress response mechanism, which is mediated by STRE-elements in the promoter of genes involved in stress protection (e.g. heat shock proteins, catalase, *TPS1* encoding trehalose-6-phosphate synthase, etc.). Hence, if the growth of the fungus is inhibited by antifungals it may also initiate the stress response. This means
10 that inhibitors that act on the trehalose-6-phosphate phosphatase lock the fungus into a vicious circle. Because it is stressed it reacts with the stress response mechanism of which stimulation of trehalose synthesis forms part. However, because the phosphatase is inhibited, trehalose-6-phosphate will be accumulated instead of trehalose and it will become even more stressed, inducing an even stronger stress response resulting in more
15 toxic trehalose-6-phosphate, and so on.

 The *tps2* mutant in *Saccharomyces cerevisiae* is not only temperature sensitive but also osmosensitive. It has been isolated as an osmosensitive mutant and the gene called *HOG2*. In tissues of organisms, water availability is usually restricted and the fungal pathogens are therefore generally osmostressed. Since inhibition of trehalose-6-
20 phosphate phosphatase renders the cells osmosensitive, the fungus will also be unable to survive because of this reason.

 The present invention includes all antifungal agents, e.g. antifungal drugs or fungicides, that inhibit enzymes converting with a low or high degree of specificity, sugar phosphates into sugars or sugar alcohol phosphates into sugar alcohols that are
25 accumulated in large quantities for instance, but not exclusively, under conditions deviating from the optimal growth condition or as a reaction to stress conditions.

 The present invention also includes all biocides acting on insects, nematodes, bacteria, worms, mites, protozoa and other organisms accumulating large quantities of trehalose and/or similar stress-protective sugars or sugar alcohols and inhibiting enzymes
30 converting with a low or high degree of specificity sugar phosphates into sugars or sugar alcohol phosphates into sugar alcohols that are accumulated in large quantities for instance, but not exclusively, under conditions deviating from the optimal growth condition or as a reaction to stress conditions. The present invention includes a screening

assay for identifying inhibitors which inhibit a first cell enzyme converting with a low or high degree of specificity a sugar phosphate into a sugar or a sugar alcohol phosphate into a sugar alcohol that are accumulated in large quantities by cells for instance, but not exclusively, under conditions deviating from the optimal growth condition or as a reaction to stress conditions, the inhibition being either directly of the enzyme or indirectly, e.g. by suppressing the expression of the corresponding gene; the method comprising the steps of:

Step 1: contacting a candidate inhibitor with a biological medium comprising the sugar phosphate or sugar alcohol phosphate and the first enzyme;

Step 2: measuring activity which depends upon the activity of the first enzyme;

Step 3: repeating steps one and two with further candidate inhibitors; and

Step 4: selecting those candidate inhibitors which reduce activity of the enzyme compared with the same medium without the inhibitor under the same conditions.

The first enzyme is preferably a phosphatase which synthesizes a sugar or sugar alcohol as a reaction to stress. The reduction in activity is preferably at least 25%, more preferably at least 50%, more preferably at least 75%, more preferably at least 85% and most preferably at least 95%. In a separate assay, the activity of the second enzyme which is involved in the synthesis of the corresponding sugar phosphate or sugar alcohol phosphate is assessed and the selecting step preferentially involves selection of inhibitors which reduce the activity of the first enzyme while maintaining a viable activity of the second enzyme. Viable activities are considered to be at least 25%, more preferably at least 50% and most preferably at least 75% of the activity of the second enzyme in the same medium under the same conditions but without the inhibitor.

The biological medium may include a pure enzyme or pure enzymes, sub-cellular organelles or sub-cellular non-organelle components (*in vitro* screening), a cell culture, or animal tissue, plant tissue or a plant or an animal (*in vivo* screening). The sub-cellular organelles or sub-cellular non-organelle components or the cell culture may be obtained from the target organism, e.g. cells from insects, worms, mites or nematodes or cells of fungi, bacteria or protozoa (e.g. mycoplasma) or any other organism with a trehalose pathway.

The first enzyme may be one or more of trehalose-6-phosphatase, glycerol-3-phosphatase, mannitol-1-phosphatase, sorbitol-6-phosphatase, arabitol-5-phosphatase, or

erythritol-4-phosphatase or any similar enzyme controlling a metabolic pathway which has an intermediary compound which is normally produced as a reaction to stress conditions and/or is toxic to the cell in high concentrations.

The present invention may provide a screening assay for an inhibitor of the first enzyme in fungi. Yeast cells are extracted by vortexing in the presence of glass beads. After clearing of the extract by low-speed centrifugation, it is desalted on a gel filtration column, i. e. Sephadex G25. The final cell extract is used to measure the activity of the first enzyme. To screen the inhibitors, different concentrations of candidate compounds are added and the residual activity of the first enzyme is measured. For example, when the first enzyme is TPP, the substrate, trehalose-6-phosphate, is added to the final cell extract and either the formation of trehalose or free phosphate is then measured. Inhibitors are selected based on their ability to inhibit TPP. Ideally, inhibitors are selected which inhibit TPP but not TPS.

Filamentous fungi may be extracted after freezing in liquid nitrogen. The frozen mycelia are extracted by grinding in a mortar. After addition of the buffer, the cell extracts are cleared by low-speed centrifugation and desalted over a Sephadex column. To screen for inhibitors, different concentrations of these compounds are added and the residual activity of the first enzyme is measured. When the first enzyme is TPP, trehalose-6-phosphate is added to the cell extracts and either the phosphate or the trehalose that is generated is measured. Inhibitors are selected based on their ability to inhibit TPP. Ideally, inhibitors are selected which inhibit TPP but not TPS.

The present invention may provide a screening assay for an inhibitor of the first enzyme in worms, e.g. nematodes. Nematodes, or worms in general, are extracted after freezing in liquid nitrogen. The frozen nematodes or worms are extracted by grinding in a mortar. After addition of the buffer, the cells are cleared by low-speed centrifugation and desalted over a Sephadex column. To screen for inhibitors, different concentrations of candidate compounds are added and the residual activity of the first enzyme is measured. When the first enzyme is TPP, trehalose-6-phosphate is added to the cell extract and either the phosphate or the trehalose that is generated is measured. Inhibitors are selected based on their ability to inhibit TPP. Ideally, inhibitors are selected which inhibit TPP but not TPS.

The present invention may provide a screening assay for an inhibitor of the first enzyme in insects or mites (Acari). Insects or mites, or parts of the insects or mites are

extracted after freezing in liquid nitrogen. The frozen insects or mites are extracted by grinding in a mortar. After addition of the buffer, the cell extracts are cleared by low-speed centrifugation and desalted over a Sephadex column. To screen for inhibitors, different concentrations of candidate compounds are added to the cell extract and the residual activity of the first enzyme is measured. When the first enzyme is TPP, trehalose-6-phosphate is added to the cell extract and either the phosphate or the trehalose that is generated is measured. Inhibitors are selected based on their ability to inhibit TPP. Ideally, inhibitors are selected which inhibit TPP but not TPS.

The present invention may provide a screening assay for an inhibitor of a first enzyme in bacteria or protozoa. Bacterial or protozoal cells are extracted by vortexing in the presence of glass beads. After clearing of the extract by low-speed centrifugation, it is desalted on a gel filtration column, i. e. Sephadex G25. The final cell extract is used to measure the TPP activity. To screen the inhibitors, different concentrations of candidate compounds are added and the residual activity of the first enzyme is measured. When the first enzyme is TPP the substrate, trehalose-6-phosphate, is added to the cell extract and either the formation of trehalose or free phosphate is then measured. Inhibitors are selected based on their ability to inhibit TPP. Ideally, inhibitors are selected which inhibit TPP but not TPS.

According to the method for the identification of enzyme inhibitors of the present invention, assays may be carried out both in whole-cell preparations or in *ex vivo* cell-free systems. In each instance, the assay target is an enzyme converting with a low or high degree of specificity a sugar phosphate into a sugar or a sugar alcohol phosphate into a sugar alcohol that are accumulated in large quantities by cells for instance, but not exclusively, under conditions deviating from the optimal growth condition or as a reaction to stress conditions, the inhibition of which enzyme significantly attenuates cell growth or is lethal. Test compounds which are found to inhibit a target enzyme in an assay of the present invention are thus identified as potential pharmaceutically or biologically active agents. It is expected that the assay methods of the present invention will be suitable for both small- and large-scale screening of test compounds, as well as in quantitative assays such as serial dilution studies wherein the target enzyme is exposed to a range of test compound concentrations.

When the method of the present invention is carried out as a whole-cell assay, the target enzyme is an intracellular enzyme and the entire, living cells are exposed to the

test compound under culture conditions in which the target enzyme is produced, e.g. during non-optimal growth, stress situations. Such conditions, including essential nutrients, optimal temperatures and other parameters, depend upon the particular fungal, bacterial, insect, nematode, worm, mite or protozoal strain being targeted. The step of
5 determining inhibition of the enzyme (step 2 above) may be carried out by observing the cell culture's growth or lack thereof; such observation may be made visually, by optical densitometric or other light absorption/scattering means, or by other suitable means, whether manual or automated.

In the above whole-cell assay, an observed lack of cell growth may be due to
10 inhibition of the target enzyme or an entirely different effect of the test compound, and further evaluation is required to establish the mechanism of action and to determine whether the test compound is a specific inhibitor of the target enzyme. Accordingly, and in a preferred embodiment of the present invention, the method may be performed as a paired-cell assay in which each test compound is separately tested against two different
15 sets of cells, the first having a lower enzyme activity than that of the second and thereby being more susceptible to inhibition of the enzyme.

Compounds which are found to inhibit the first, more susceptible cells but not the second are likely to have acted specifically on the target enzyme and not via a different mechanism.

20 One manner of achieving differential susceptibility is by using a first cell which has diminished enzyme activity relative to that of a wild-type cell, as for example a mutant strain.

Alternatively, or in conjunction with the above, differential susceptibility to target enzyme inhibitors may be obtained by using a second fungal cell which has increased
25 enzyme activity relative to that of a wild-type cell, as for example one which has been genetically manipulated to cause overexpression of the enzyme. Such overexpression can be achieved by placing into a wild-type cell a plasmid carrying the gene for the target enzyme.

Preferred is a method in which the differentiated target enzyme activity is
30 produced by subjecting one set of cells to a stress or non-optimal growth situation which favors enzyme activity and a second control set without the stress or non-optimal growth promoter.

The present invention also includes any inhibitor found by any of the above

screening assays. In particular, the present invention includes any inhibitor found by any of the above screening assays used in a pharmaceutical preparation either alone or in combination with an antifungal drug. The present invention also includes any inhibitor found by any of the above screening assays used in a biocide acting on insects,
5 nematodes, worms, mites, bacteria, protozoa or other organisms accumulating large quantities of a sugar alcohol or a sugar in response to stress.

The present invention also includes a screening assay for identifying inhibitors which inhibit a first cell enzyme converting with a low or high degree of specificity a sugar phosphate into a sugar or a sugar alcohol phosphate into a sugar alcohol that are
10 accumulated in large quantities by cells for instance, but not exclusively, under conditions deviating from the optimal growth condition or as a reaction to stress conditions, the inhibition being either directly of the enzyme or indirectly, e.g. by suppressing the expression of the corresponding gene; the method comprising the steps of:

15 Step 1: contacting a candidate inhibitor with a biological medium comprising the sugar phosphate or sugar alcohol phosphate and the first enzyme;

Step 2: measuring activity which depends upon the activity of the first enzyme;

Step 3: repeating steps one and two with further candidate inhibitors;

20 Step 4: selecting those candidate inhibitors which reduce activity of the enzyme compared with the same medium without the inhibitor under the same conditions.

Step: 5 contacting the selected candidate inhibitors with a biological medium comprising whole cells having the first enzyme as an intracellular enzyme; and

25 Step 6: selecting those candidate inhibitors which reduce the growth of the cells.

DEFINITIONS

The term "intracellular inhibitor", as used herein, refers to inhibitors which are able to penetrate target cells, or which are taken up by target cells, and which exhibit
30 inhibitory activity inside the target cell. The inability to penetrate the cell (non-permeability), rapid degradation of a compound or a conversion to inactive forms once inside the cell are possible reasons for a compound to be non-active *in vivo*.

The term "target cell", as used herein, refers to yeast, fungals, bacterial,

protozoal, nematodal, worm, mite or insect cells, or cells of any other organism exhibiting enzymatic TPP activity or, more in general, the sugar alcohol phosphatases or sugar phosphatases of the present invention.

The terms "specifically", "impairing specifically" and "slowing down the growth specifically of", as used herein, refer to the fact that preferentially the inhibitor impairs the action of the phosphatases only, and more specifically TPP only, in a target cell but not in cells of a host organism infected by the target cells. As such only target cells with TPP activity will be affected in their growth. Preferentially, the inhibitors of the present invention will not interfere with any metabolic pathway of the host.

The term "host" or "host organism", as used herein, refers to a human, an animal or a plant infected by the target cells.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 gives a representation of the trehalose biosynthesis in *Saccharomyces cerevisiae* as a two step process.

Figures 2A and B show the growth curves of prototrophic *S. cerevisiae* wild-type and *tps2Δ* strains in the presence of different concentrations of Itraconazole at 37°C, respectively. Closed symbols: wild-type (WT); open symbols: *tps2Δ* (♦): DMSO; (■): 10⁻⁸M; (▲): 10⁻⁷M, (—, ○): 10⁻⁶M; (x, ✱): 10⁻⁵M Itraconazole (itra).

Figure 3 shows the growth curves of prototrophic *S. cerevisiae tps2Δ* and wild-type strains in the presence of 10⁻⁷ M of Itraconazole at 33°C. Closed symbols: wild-type (WT); open symbols: *tps2Δ* (♦): DMSO; (●): 10⁻⁷M Itraconazole (itra).

Figure 4 shows the growth curves of prototrophic *S. cerevisiae tps2Δ* (PVD23) and wild-type (PVD32) strains in the presence of 10⁻⁶ M of Ketoconazole at 33°C. Closed symbols: wild-type (WT); open symbols: *tps2Δ* (♦): DMSO; (●): 10⁻⁶M Ketoconazole (keto).

Figures 5A and B show the growth curves of diploid prototrophic wild-type *S. cerevisiae* (PVD190) and diploid heterozygous *S. cerevisiae tps2Δ* (PVD191) strains in the presence of different concentrations of Itraconazole at 33°C. Closed symbols: wild-type (WT); open symbols: heterozygous *tps2Δ* (♦): DMSO; (■): 10⁻⁸M; (▲): 10⁻⁷M;

(*): 3×10^{-7} M; (—): 10^{-6} M; (●): 3×10^{-6} M.

Figure 6 shows the effect of Itraconazole on the growth of wild-type *S. cerevisiae* (PVD32) and *S. cerevisiae tps2Δ* (PVD23) strains on YPD plates.

Figure 7 shows the effect of osmotic and heat stress on the growth of wild-type *S. cerevisiae* (PVD32) and *S. cerevisiae tps2Δ* (PVD23) strains on YPD plates.

Figure 8 shows the alignment for maximal amino acid similarities of trehalose phosphate phosphatase derived from *S. cerevisiae* (GENBank accession number 577801) with a homologous sequence from *C. albicans* (*C. albicans* database, <http://www-sequence.stanford.edu/group/candida>), with indication of the 2 putative phosphatase boxes (bold italic and underlined). Identical residues are indicated by an asterisk (*). Gaps in the amino acid sequence are represented by dots (--). A colon (:) stands for strong similarity, a dot (.) stands for weak similarity. The CLUSTAL W (1.8) multiple sequence alignment software was used.

Figure 9 shows the genomic organisation of the *C. albicans* *TPS2* gene, *CaTPS2*, and its flanking regions (5598 bp in total) with indication of the oligonucleotide primers used to isolate and amplify the gene (FOR2 and REV2), primers used to check for deletions in the strains (e.g. 3' diag and 5' diag) and with the relevant restriction sites.

Figure 10 shows the complete cloning strategy used to obtain the *C. albicans* pUC19/*Catps2Δ::HisGURA3HisG* disruption construct.

Figure 11 shows a Southern blot analysis for 14 heterozygous *TPS2/tps2Δ* CAI4 transformants as obtainable by using the *TPS2* disruption cassette. The presence of two bands, one of 3224 and one of 2874 bp confirm the heterozygous character. 10 μg of DNA was digested with *Eco*RI and fragments electrophoresed. Hybridization was performed with the P³²-labelled 579 bp *Sna*BI- *Hind*III fragment corresponding to the 3' flanking site of *CaTPS2* gene. Left: molecular weight marker VII from Boehringer; Lanes 1-14: putative heterozygous *TPS2/tps2Δ* *C. albicans* mutants.

Figure 12 A shows the results of a PCR analysis with a set of three primers: Diag3, Diag5 and DiagHIS4. Left: Smart ladder molecular weight marker (Eurogentec) Lanes 1-4: putative *C. albicans* double deletion transformants. 10 μl of a standard PCR reaction mixture was loaded on a 1% agarose gel. Lane 2 corresponds with a putative double deletion mutant. Figure 12 B shows the results of a Southern blot analysis used for the identification and verification of putative double strain mutants. 10 μg of DNA

was digested with *EcoRI* and fragments electrophoresed. Hybridization was performed with the P^{32} -labelled 579 bp *SnaBI*-*HindIII* fragment corresponding to the 3' flanking site of *CaTPS2* gene. Left: molecular weight marker VII from Boehringer; Lanes 1-5, 7-10: putative *C. albicans* double deletion mutants.

5 **Figures 13 A and B** show the growth curves at 41°C (closed symbols) and 43°C (open symbols) of the three different *C. albicans* strains, *TPS2/TPS2* (wild-type, SC5314), *TPS2/tps2Δ* (heterozygous deletion mutant, CC5) and *tps2Δ/tps2Δ* (homozygous deletion mutant, CC17) respectively, grown on YPgalactose (A) and YPglucose (B) medium respectively. (●, ○): *TPS2/TPS2*; (■, □): *TPS2/tps2Δ*; (▲, Δ): *tps2Δ/tps2Δ*.

10 **Figures 14 and 15** show the inhibition of trehalose-6-phosphate activity in *S. cerevisiae* strain PVD45 by NEM and DTNB. (14) bars from left to right respectively stand for: 35 mM; 3.5 mM; 0.35 mM; 0.035 mM; 0 mM. (15) (♦): NEM; (■): DTNB.

15 **Figure 16** shows the screening assay in accordance with the present invention for the determination of TPP activity and inhibition thereof in cell extracts using the Biomek robotic system and screening the DIVERSet™ (Chembridge, San Diego) compound library. (1): stock plates (10^{-2} M); (2): working plates (10^{-3} M); (3): 2 μl test compound (or DMSO or DTNB) + 148 μl mix1 (40 μl tricine buffer 200 mM pH7; 20 μl $MgCl_2$ 0.1 M; 20 μl trehalose-6-phosphate 25 mM; 68 μl H_2O) + 10 μl extract (final protein

20 concentration of about 10 mg/ml), incubation for 30 min at 30°C in the Biomek robotic system, 1G=2 μl pure DMSO, 1H= 2 μl DTNB (10^{-3} M in DMSO); (4): 15 μl of (3) or 15 μl of an orthophosphate (Pi) standard series (0, 0.02, 0.1, 0.2, 1 and 5mM in H_2O) + 148 μl molybdate/Zn acetate (100mM/15mM, pH5) + 37 μl ascorbic acid (10% in H_2O at (pH5), freshly prepared), 1A-1F: Pi standard series, incubation for 20 min at 30°C in the

25 Biomek robotic system; (5) OD_{750} measurement using a SPECTRAMAX spectrophotometer.

30 **Figure 17** shows the structure of 7 potential TPP inhibitors identified in accordance with the present invention from the DIVERSet™ (Chembridge, San Diego) compound library. The identified compounds perform equal to or better than DTNB at 10^{-5} M under the circumstances as given. Numbers refer to the number given to the compound in the DIVERSet™ compound library. A: compound 136794; B: compound 143067; C: compound 113596; D: compound 113610; E: compound 133207; F:

compound 133805; G: compound 100764

Figure 18 shows the *in vitro* inhibitory activity on *S. cerevisiae* trehalose phosphate phosphatase of 6 different DiverSet™ compounds, tested in 7 different concentrations. Bars, from left to right respectively stand for: 0M, 3×10^{-5} M, 1×10^{-5} M, 3×10^{-6} M, 1×10^{-6} M, 3×10^{-7} M, 1×10^{-7} M. Compounds are: (1) 136794; (2) 109146; (3) 143067; (4) 116321; (5): 145704; (6) DTNB.

Figures 19 A and B show the growth curves at 37°C of the wild-type *S. cerevisiae* (W303.1A) strain in the presence of different concentrations (0, 10^{-5} , 10^{-6} , 10^{-7} , and 10^{-8} M respectively) of inhibitory compounds 136794 (A) and 143067 (B). (●): wild-type PVD517 strain; (■): compound at 10^{-8} M; (▲): compound at 10^{-7} M; (○): compound at 10^{-6} M; (*, asterisk): compound at 10^{-5} M

Figures 20 A and B show the growth curves at 43°C of a wild-type *C. albicans* strain (SC5314) in the presence of inhibitory compounds 133207 (■), 133805 (□), 113610 (▲), DTNB (Δ), NEM (○) or DMSO (●). Test compounds were added at two different concentrations: 10^{-5} M (A) and 10^{-7} M (B).

Figures 21 A and B show the growth curves at 39°C of a *C. albicans* *tps2Δ/tps2Δ* strain (CC17) in the presence of inhibitory compounds 133207 (■), 133805 (□), 113610 (▲), DTNB (Δ), NEM (○) or DMSO (●). Test compounds were added at two different concentrations: 10^{-5} M (A) and 10^{-7} M (B).

Figure 22 shows the growth curves at 43°C of a wild-type *C. albicans* strain (SC5314) in the presence of inhibitory compounds 100764 (Δ), 136794 (○), 143067 (▲), 113610 (◆) or DMSO (●). Test compounds were added at 10^{-7} M in DMSO.

DESCRIPTION OF THE ILLUSTRATIVE EMBODIMENTS

The present invention will be mainly described with reference to trehalose-6-phosphate and yeast cells but the present invention is not limited thereto but only by the claims. In particular the present invention may find advantageous use in the control, including human, animal or plant therapeutic control of fungi, nematodes, worms, bacteria, protozoa, mites and insects.

Fig. 1 is a schematic representation of the metabolic pathway within yeasts, other fungi, bacteria, protozoa, nematodes, worms, mites (Acari), insects and other organisms

producing trehalose. Trehalose is synthesized from glucose-6-phosphate and UDP-glucose, catalyzed by trehalose-6-phosphate synthase (TPS), which is encoded by the gene *TPS1* in yeast, to form trehalose-6-phosphate which is further processed to trehalose by trehalose-6-phosphatase (TPP) which is encoded by the gene *TPS2* in yeasts. Further,
5 additional genes *TPS3* and *Ts11* are believed to encode proteins which only play a regulatory role.

The promoters of the *TPS1* and *TPS2* genes are highly stress dependent and TPS is very active under bad growth conditions such as during growth on non-fermentable carbon sources, during nutrient limitation, e.g. during the stationary phase and during
10 growth at high temperatures. Inhibition of the TPP enzyme or mutation or elimination of the *TPS2* gene while leaving the TPS enzyme intact, results in an increase in the trehalose-6-phosphate levels in the cell under conditions where wild-type cells accumulate trehalose. The present inventors have been the first to determine that specific inhibition of the TPP enzyme while maintaining the activity of the TPS enzyme makes
15 the cell more prone to attack by antifungal agents. That is, the amount of antifungal agent required to stop growth or to kill the cell is reduced. This is particularly advantageous as the commonly used antifungal agents have serious side effects and any method of reducing the concentrations having a significant therapeutic effect is valuable. The trehalose metabolic pathway does not play an important role in humans and other
20 mammals, so that a specific inhibitor to TPP, offers the possibility of reduced, few or no side effects. The present invention therefore sets as one of its objects the development of a specific inhibitor for TPP. Accordingly, embodiments of the present invention relate to a screening assay for detecting specific inhibitors of TPP. With "specific" is meant that the inhibitor (preferably) interferes with TPP only and not with phosphatases or any
25 essential metabolic pathway of the host, e.g. a human, animal or plant in need of treatment.

MATERIALS AND METHODS

30 MEASUREMENT OF TREHALOSE -6-PHOSPHATASE ACTIVITY

Methods for the measurement of trehalose-6-phosphatase activity may comprise methods for the measurement of the trehalose that is released from trehalose-6-phosphate and/or the measurement of the phosphate that is released from the trehalose-6-phosphate.

1. Preparation of the extracts :

- a) cultures are grown to the desired density and are cooled quickly on ice;
- b) preferably, at least 400 mg of cells are harvested by centrifugation for 3 min at 3000 rpm;
- c) cells are washed twice with ice-cold distilled water;
- d) cells are resuspended in 990 μ l extraction buffer consisting of 968 μ l of 50 mM Imidazole (Merck 1.04716 (RT)), 2 μ l of 0.5 M EDTA (Tritriplex III Merck 1.08418 (RT)), 20 μ l of 0.1 M $MgCl_2$ (UCB 94046076 (RT)),
- e) cells are transferred to screw capped tubes and an equivalent of 0.5 ml glass beads with 0.5 mm diameter are added;
- f) just before extraction 10 μ l of a 100 mM PMSF solution (Sigma P7626 (RT)) in methanol is added to the cell mixture ;
- g) the extraction is performed in a Fastprep apparatus (BIO101) for 20 seconds at level 4, and is repeated three times with a cooling step on ice in between.
- Alternatively the extraction can be performed on a vortex apparatus in glass tubes (always used for large scale preparations);
- h) extracts are centrifuged at 4°C for 20 min at 14000 rpm;
- i) 20 μ l of the supernatant is loaded on a small Sephadex G25 column, made in a blue tip containing a siliconized glass bead. The tip is filled completely with pre-equilibrated G25 Sephadex (50 mM Tricine (Sigma T-0377 (RT)) buffer (pH7). The tips are centrifuged once before application of the extract for 1 min at 800 rpm. The extract is centrifuged for 1 min at 1000 rpm;
- j) 200 μ l of the eluate is added to 140 μ l Assay I solution consisting of 40 μ l of 200 mM Tricine buffer (pH7), 20 μ l of 0.1 M $MgCl_2$, 20 μ l of 25 mM trehalose-6-phosphate (Sigma) and 60 μ l H_2O . For the Assay I control mixture 20 μ l trehalose-6-phosphate is omitted and replaced by 20 μ l H_2O .
- k) the assay mixture and the control mixture are incubated for 30 min at 30°C;
- l) the assay mixture and the control mixture are boiled for 5 min and cooled down to room temperature.
- m) centrifugation of the micro-centrifuge tubes for 5 min at 14000 rpm

For large scale screenings to identify specific enzyme inhibitors, whereby bigger

amounts of yeast extracts are required, loading on small Sephadex G25 columns (step i) is replaced by loading on a superdex200 column (Amersham Pharmacia biotech). Briefly, about 500 µl of extract (protein concentration about 15 mg/ml) in extraction buffer (see step (d) above) is loaded on a superdex200 column equilibrated with this same extraction
5 buffer. For each run, 500 µl of sample was loaded on the column, which was then eluted at 0.5 ml/min with a total buffer volume of 35.5 ml. 750 µl fractions were collected and the FPLC fractions containing TPP activity (fractions 11-13) pooled. These pooled fractions were then concentrated on VIVASPIN columns (VIVAscience) by a 30 min centrifugation step at 3500 rpm. The final protein concentration of the extract used for
10 screening was about 10 mg/ml (method of Lowry, J. Biol. Chem. 193, 265-275, 1951). Alternative methods for determination of protein contents are well known in the art. Further steps were as described above (steps j to m).

2. Measurement of trehalose that is released from trehalose-6-phosphate.

15 One method of calculating the amount of trehalose released from trehalose-6-phosphate is by performing two steps: the hydrolysis of trehalose by trehalase and the measurement of the resulting glucose by either the glucose-oxidase/peroxidase reaction, or the use of the Trinder reagent.

a) Hydrolysis of trehalose by trehalase.

The trehalase is obtained from the fungus *Humicola grisea var. thermoidea*. The organism is grown at 40°C on a solid medium containing 4% oat and 1.8% agar. The isolation and purification of the trehalase from this fungus is performed according to Neves et al. (FEBS Lett. 283, 19-22, 1991).

25 After preparation and centrifugation of the extracts according to the methods described above, 30 µl of the extract is transferred to new microcentrifuge tubes, and 10 µl buffer (300 mM NaAc, 30 mM CaCl₂, pH 5.5) and 40 µl trehalase solution (400 U/ml) is added. The mixture is incubated at 40°C for 45 min.

A trehalose standard curve of 0,1,2,4,8 and 10 mM is also analyzed.

30

b) Measurement of the glucose from the hydrolysis of trehalose by trehalase by oxidation of glucose by glucose-oxidase/peroxidase.

Materials:

Solution A: containing 3.75 mg glucose-oxidase (100 U/mg), 8 mg peroxidase (100 U/mg) and 2.25 ml Tris/Cl (1M pH8) adjusted to 100 ml with water.

Solution B: containing 10 mg/ml ortho-dianisidine-diHCl.

5 The glucose-oxidase solution is prepared just before use by mixing 1 ml of solution B with 100 ml solution A.

The method involves the transfer of 60 µl of the product of the trehalase reaction to a glass tube, adding 1 ml of the glucose-oxidase solution, incubating for 60 min at 30 °C. The reaction is terminated by adding 0.5 ml H₂SO₄ (56%) to the reaction mixture. The OD of the reaction mixture is measured at 546 nm.

10 A glucose standard curve with 0, 1, 2, 3 and 4 mM is analyzed at the same time.

c). Measurement of the glucose from the hydrolysis of trehalose by trehalase by oxidation of glucose using Trinder reagent.

15 The glucose produced from the hydrolysis of trehalose by trehalase can also be measured using the Trinder reagent (SIGMA), which is based on the same principle as the glucose oxidase reaction.

The method involves the transfer of 20 µl of the end products of the trehalase reaction in a microtiter plate well, the addition of 200 µl Trinder reagent and mixing by shaking and incubating for 15 min at 30°C. The OD of the sample is determined at 505 nm in the microtiter plate reader (Spectramax).

20 A glucose standard curve with 0, 1, 2, 3 and 4 mM is analyzed at the same time.

d) Calculation of the TPP activity.

25 Following the hydrolysis of trehalose by trehalase and the measurement of the resulting glucose by the glucose-oxidase/peroxidase reaction, the TPP activity can be calculated by dividing the OD of a sample by the time of the reaction and by the protein content (expressed as nKat/g protein).

Alternatively the trehalose that is formed by the action of the trehalose-6-phosphate enzyme can be measured by the HPLC analysis on a CarboPac PA-100 anion-exchange column as described by De Virgilio et al. (Eur. J. Biochem.212, 315-2-323, 1993).

3. Measurement of the phosphate released from the trehalose-6-phosphate.

Apart from the trehalose, the phosphate can also be measured that is released by the action of the trehalose-6-phosphate phosphatase enzyme.

This can be performed by either one of the following methods:

- a) Continuous phosphate measurement using the EnzChek™ Phosphate Assay Kit (Bioprobes, Molecular Sondes). In the presence of free Pi, the substrate 2-amino-6-mercapto-7-methylpurine riboside (MESG) with maximum absorbance at 330 nm, is converted by the action of the enzyme purine nucleoside phosphorylase (PNP) to a product with maximum absorbance at 360 nm (2-amino-6-mercapto-7-methylpurine). The increase in absorbance at 360 nm is monitored spectrophotometrically and is proportional to the phosphate consumption by the MESG/PNP reaction.
- b) Free phosphate measurement by the method of Bencini (Anal. Biochem. 132: 254-258, 1983). The reagent solution, an aqueous mixture of ammonium molybdate (100 mM) and zinc acetate (15 mM) at pH 5, produces a stable complex with orthophosphate (Pi). This complex is reduced by the addition of ascorbic acid (10% in H₂O (pH5), freshly prepared), whereby a product is formed that absorbs strongly at 850 nm. Measurements can be performed equally well at 750 nm. The method is linear up to 300 µM phosphate.
- c) The measurement of phosphate according to the method of Fiske-Subbarow comprises:
 1. the addition of 900 µl of 0.5% ammonium molybdate in 0.8N HCl to each sample;
 2. the addition of 100 µl of Fiske-Subbarow solution (0.025% 1-amino-2-naftol-4-sulfonic acid + 0.5% Na₂SO₃ + 15% Na₂S₂O₅);
 3. after incubation at room temperature for 30 min, the OD is measured at 700 nm;
 4. the protein concentration is determined by the method of Lowry (Lowry et al., J. Biol. Chem. 193, 265-275, 1951)
- d) The measurement of free phosphate using glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate kinase in a linked enzyme assay according to Trentham et al. (Biochem. J. 126, 635-644, 1972).

4. Measurement of TPP activity using radioactive trehalose-6-phosphate as substrate

Alternatively TPP activity can be measured by direct measurement of radioactive phosphate using radioactive trehalose-6-phosphate in the extracts as has been described by Vuorio et al. (Eur. J. Biochem. 216, 849-861, 1993). The method comprises the following steps:

- 5 a) cultures are grown to the desired density and are cooled quickly on ice;
- b) preferably, at least 400 mg of cells are harvested by centrifugation for 3 min at 3000 rpm;
- c) cells are washed twice with ice-cold distilled water;
- d) cells are resuspended in 990 μ l extraction buffer consisting of 968 μ l of 50 mM Imidazole (Merck), 2 μ l of 0.5 M EDTA (Tritriplex III Merck), 20 μ l of 0.1 M $MgCl_2$ (UCB),
- 10 e) cells are transferred to screw capped tubes and an equivalent of 0.5 ml glass beads with 0.5 mm diameter are added;
- f) just before extraction 10 μ l of a 100 mM PMSF solution (Sigma) in methanol; is
- 15 added to the cell mixture ;
- g) the extraction is performed in a Fastprep apparatus (BIO101) for 20 seconds at level 4, and is repeated three times with a cooling step on ice in between.
- Alternatively the extraction can be performed on a vortex apparatus in glass tubes;
- 20 h) extracts are centrifuged at 4°C for 20 min at 14000 rpm;
- i) 200 μ l of the supernatant is loaded on a small Sephadex G25 column, made in a blue tip containing a siliconized glass bead. The tip is filled completely with pre-equilibrated G25 Sephadex (50 mM Tricine (Sigma) buffer pH7). The tips are centrifuged once before application of the extract for 1 min at 800 rpm. The
- 25 extract is centrifuged for 1 min at 1000 rpm;
- j) 5 μ l of the eluate is added to 45 μ l assay solution consisting of 27.5 mM Tris-Cl (pH7.4), of 5.5 mM $MgCl_2$, 1 mg/ml BSA and 0.55 mM trehalose-6-phosphate (specific activity 854 cpm/nmol);
- k) the assay mixture and the control mixture are incubated for 1 hour at 30°C;
- 30 l) the assay mixture is boiled for 5 min to stop the reaction;
- m) AG1-X1 is added to the mixture and the mixture is incubated for 20 min at room temperature.
- n) centrifugation of the micro-centrifuge tubes for 5 min at 14000 rpm

o) after centrifugation 400 µl of the supernatant is counted in a liquid scintillation counter.

5 *SACCHAROMYCES CEREVISIAE* STRAINS USED INCLUDING THE *TPS2Δ* MUTANT

The following *S. cerevisiae* strains were used in the experiments :

Name	Relevant genotype	Complete genotype
W303.1A	Wild-type	<i>a leu2-3,112 ura3-1 trp1-1 his3-11,15 ade2-1 can1-100 GAL SUC2</i>
YSH448	<i>tps2Δ</i>	<i>a leu2-3,112 ura3-1 trp1-1 his3-11,15 ade2-1 can1-100 GAL SUC2 tps2Δ::HIS3</i>
PVD32	W303.1A prototrophic	
PVD23	<i>tps2Δ</i> prototrophic	
PVD45	YE ϕ TPS2	<i>a leu2-3/112 ura3-1 trp1-1 his3-11,15 ade2-1 can1-100 GAL SUC2 tps1Δ::TRP1 tps2Δ::LEU2 + pSAL4/TPS2 (URA3)</i>
YSH339	W303.1A alpha	alpha <i>leu2-3,112 ura3-1 trp1-1 his3-11,15 ade2-1 can1-100 GAL SUC2</i>
PVD190	heterozygotic W303 diploid	<i>leu2-3,112 / LEU2 ura3-1 / URA3 trp1-1 / TRP1 his3-11,15 / HIS3 ade2-1 / ADE2 can1-100 GAL SUC2</i>
PVD191	<i>tps2Δ</i> / WT diploid	<i>leu2-3,112 ura3-1 / URA3 trp1-1 / TRP1 his3-11,15 / HIS3 ade2-1 / ADE2 can1-100 GAL SUC2 tps2Δ::LEU2</i>

The construction of the prototrophic *S. cerevisiae* strains was performed as follows:

10 1. Construction of PVD32.

W303.1A was first transformed (LiAc method according to Gietz et al (1992), Nucleic Acids Research 20: 1425 – Gietz et al (1995), Yeast 11: 355-60) with a plasmid containing the *HIS3* marker. Unless otherwise stated, all yeast transformation steps were performed in accordance with this method. The plasmid pJJ215 was linearized with *Nhe*I,

which cuts in the marker. The complete plasmid will integrate at the location of the *his3* marker and as a result one wild-type *HIS3* marker is present in the genome. The resulting strain is PVD1: W303-1A *HIS3*.

Subsequently PVD1 was transformed with a plasmid containing the *URA3* marker. The
5 plasmid YIplac 211 was linearized with *EcoRV*, which cuts the marker. The complete
plasmid will integrate at the location of the *URA3* marker and as a result one wild-type
URA3 marker is present in the genome. The resulting strain is PVD2: W303-1A *HIS3*
URA3. PVD2 was transformed with a plasmid containing the *LEU2* marker. The plasmid
YIplac128 was linearized with *EcoRV*, which cuts in the marker. The complete plasmid
10 will integrate at the location of the *leu2* marker and as a result one wild-type *LEU2*
marker is present in the genome. The resulting strain is PVD16: W303-1A *HIS3 URA3*
LEU2. PVD6 was transformed with a plasmid containing the *ADE2* marker. The plasmid
pASZ10 was linearized with *EcoRV*, which cuts in the marker. The complete plasmid
will integrate at the location of the *ade2* marker and as a result one wild-type *ADE2*
15 marker is present in the genome. The resulting strain is PVD29: W303-1A *HIS3 URA3*
LEU2 ADE2. Finally, PVD29 was transformed with a plasmid containing the *TRP1*
marker. The plasmid YIplac204 was linearized with *EcoRV*, which cuts in the marker.
The complete plasmid will integrate at the location of the *trp1* marker and as a result one
wild-type *TRP1* marker is present in the genome. The resulting strain is PVD32: W303-
20 1A *HIS3 URA3 LEU2 ADE2 TRP1*.

2. Construction of PVD23

YSH448 was first transformed with a plasmid containing the *HIS3* marker. The
plasmid pJJ215 was linearized with *Nhe1*, which cuts in the marker. The complete
25 plasmid will integrate at the location of the *his3* marker, and as a result one wild-type
HIS3 marker is present in the genome. The resulting strain is PVD11: *tps2Δ::LEU2 HIS3*.
PVD11 was subsequently transformed with a plasmid containing the *URA3* marker. The
plasmid YIplac211 was linearized with *EcoRV*, which cuts in the marker. The complete
plasmid will integrate at the location of the *URA3* marker and as a result one wild-type
30 *URA3* marker is present in the genome. The resulting strain is PVD7: *tps2Δ::LEU2 HIS3*
URA3. PVD7 was transformed with a plasmid containing the *TRP1* marker. The plasmid
YIplac204 was linearized with *EcoRV*, which cuts in the marker. The complete plasmid

will integrate at the location of the *trp1* marker and as a result one wild-type *TRP1* marker is present in the genome. The resulting strain is PVD18: *tps2Δ::LEU2 HIS3 URA3 TRP1*. Finally, PVD18 was transformed with a plasmid containing the *ADE2* marker. The plasmid pASZ10 was linearized with *EcoRV*, which cuts in the marker. The complete plasmid will integrate at the location of the *ade2* marker and as a result one wild-type *ADE2* marker is present in the genome. The resulting strain is PVD23: *tps2Δ::LEU2 HIS3 URA3 TRP1 ADE2*.

3. Construction of PVD190.

Strain PVD190 is a diploid *S. cerevisiae* strain made by a cross between the W303 prototrophic strain (PVD32) and the W303 haploid auxotrophic strain (YSH339).

4. Construction of PVD191.

Strain PVD191 is a diploid strain made by a cross between the *tps2Δ* prototrophic strain (PVD32) and the W303 haploid auxotrophic strain (YSH339).

Methods for integrative transformation of yeast cells and other useful recommendations can be found in Ausubel et al (1999), "Short Protocols in Molecular Biology, 4th ed. John Wiley & Sons, New York", and unit 13.10 in particular.

CONSTRUCTION OF THE *CANDIDA ALBICANS* DOUBLE *TPS2Δ* KNOCK OUT MUTANT

The following *C. albicans* strains were used in the experiments :

Name	Relevant genotype	Complete genotype
SC5314	Wild-type	Clinical isolate
CAI4	<i>ura3Δ/ura3Δ</i>	<i>ura3Δ::imm434/ ura3Δ::imm434</i>
CC5	<i>TPS2/tps2Δ</i>	<i>ura3Δ::imm434/ ura3Δ::imm434</i> <i>TPS2/tps2Δ::URA3</i>
CC17	<i>tps2Δ/ tps2Δ</i>	<i>ura3Δ::imm434/ ura3Δ::imm434</i> <i>tps2Δ::URA3/ tps2Δ::URA3</i>

The construction of these *C. albicans* strains is described hereinbelow.

1. Genomic DNA isolation from yeast cells

All DNA procedures, including DNA isolation from *Candida albicans* yeast cells, are performed according to standard protocols (Sambrook et al. (1989) in "Molecular Cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, CSH, New York"; Ausubel et al (1994) in "Current Protocols in Molecular Biology, Current Protocols, USA. John Wiley & Sons, New York"; Ausubel et al (1999) in "Short Protocols in Molecular Biology, 4th ed. John Wiley & Sons, New York").

2. Isolation and cloning of the *Candida albicans* TPS2 sequence (*CATPS2*)

A *Candida albicans* sequence homologous to the *Saccharomyces cerevisiae* TPS2 gene was found in the *Candida albicans* database (<http://www-sequence.stanford.edu/group/candida>). This sequence, located in contig 4-3098, is further referred to as the *Candida albicans* TPS2 gene, or *CaTPS2*. Both sequences were aligned for maximal amino acid similarities by making use of the CLUSTAL W (1.8) multiple sequence alignment software. Conserved regions of the amino acid sequences were aligned to give the best fit. Identical residues are indicated by an asterisk (*). Gaps in the amino acid sequence are represented by dots (--). A colon (:) stands for strong similarity, a dot (.) stands for weak similarity. The two putative phosphatase boxes are indicated in bold italic and are underlined.

The *CaTPS2* gene and its flanking sites were then isolated from a *Candida albicans* wild-type strain SC5314, using the following 30 and 31 bp oligonucleotide primers (Pharmacia) for PCR (Polymerase Chain Reaction) amplification:

CaTPS2FOR2: 5' GAGTCGACCTCACCTGAGGCATCCACATAC 3'

CaTPS2REV2: 5' GAGGTACCGTGTAATCCGGACATTAACCTCCG 3'

whereby the forward primer (FOR2) contains the recognition site for the restriction enzyme *SaII* and the reverse primer (REV2) that of *KpnI* (see boxes).

PCR amplifications (30 cycles) and analysis were performed according to standard protocols (for references see above). PCR amplification with the designed

primers (Pharmacia) yielded a fragment of 3171 bp long, which contains apart from the *TPS2* reading frame an additional 523 bp upstream and 639 bp downstream sequences.

3. Construction of the *C. albicans* disruption construct

5 Both the PCR fragment containing the *TPS2* sequence and the cloning plasmid pUC19 (New England Biolabs) were digested with *SaII* and *KpnI*, and after separation on a 1% agarose gel, subsequent slicing and elution, the PCR product was ligated into the cloning vector, to form the 6470 bp pUC19/*CaTPS2* with which *E. Coli* cells were then transformed via the CaCl_2 method (Ausubel et al (1999) in "Short Protocols in Molecular Biology, 4th ed. John Wiley & Sons, New York", unit 1.8). Alternative transformation methods are well known in the art. The DNA of one of the positive colonies was then digested with the restriction enzymes *SnaBI* and *NsiI*, cutting just in the beginning and at the end of the *CaTPS2* open reading frame, leaving only 8 and 10 amino acids at the C- and N- terminus respectively. The large fragment (3885 bp) thus contains the vector plus the flanking sites of the *CaTPS2* gene. In this vector, the *HisG-URA3-HisG* cassette was cloned. The *URA3* blaster cassette, located on a fragment of 3948 bp, was isolated from plasmid pMB7-A (Fonzi W.A. and Irwin M.Y. (1993), Genetics 134: 717-728) via digestion with *BglII*, Klenow fill in of the sticky ends and digestion with *PstI*. This cloning strategy resulted in the 7384 bp pUC19/*Catps2* Δ ::*HisGURA3HisG* vector. The final disruption construct (pUC19/*Catps2* Δ ::*HisGURA3HisG*) is digested with *AvrII* and *SpeI* and the 4814 bp fragment containing the flanking sites of the *CaTPS2* gene and the *URA3* blaster cassette used to transform cells of CAI4 *Candida albicans* *URA3*⁻ strains (*ura3::imm434/ura3::imm434*). Once again, all DNA manipulations and procedures, like restriction, ligation, elution via gel electrophoresis etc., were performed according to standard protocols (for references see above).

4. Generation of a heterozygous *C. albicans* *TPS2/tps2* Δ strain

Competent CAI4 cells were prepared using a modified LiAc (Lithium acetate) method (Sanglard et al (1996), Antimicrobiol. Agents Chemother. 40: 2300-2305). Briefly, yeast cells are grown, harvested and pelleted as recommended. Cells are then resuspended in buffered lithium solution, freshly prepared. Next, 50 μl of this yeast cell suspension was added to 300 μl of PEG solution (PEG4000 of Merck), together with 50

µg of carrier DNA (sperm carrier DNA from Clontech, Yeastmaker carrier DNA Cat No. K1606-A) and 30 µg of the DNA fragment. After mixing, the cells were incubated at 30 °C for 1 hour in an incubator with shaker. Subsequently they were given a heat shock at 42 °C for 15 min. After a brief centrifugation step (about 15 sec), the supernatant was removed and the cells were resuspended in 300 µl of 1x TE buffer. The cells were plated on SDglucose-ura containing plates and incubated at 30°C for 2 to 3 days. 14 transformants were obtained as such. Colonies were picked up after three days.

Alternative methods for introduction of DNA into yeast cells comprise spheroplast transformation and transformation by electroporation, methods well known by those skilled in the art. The standard LiAc method is described in Ausubel et al (1999) in "Short Protocols in Molecular Biology, 4th ed. John Wiley & Sons, New York", unit 13.7 and unit 13 in general)

PCR analysis with a Diag3 (3' diag) 19 bp oligonucleotide primer (Pharmacia), annealing to the flanking sites of the *CaTPS2* gene outside of the fragment that has been used for the disruption, and with DiagHIS4, a 18 bp oligonucleotide primer (Pharmacia) annealing to a nucleotide sequence in the *HisG* sequence was used to verify the deletion of one of the *TPS2* alleles.

Diag3: 5' CCTTCATCGCCTGACTGAT 3'

DiagHIS4: 5' GCGTAAGCGGGTGTGTC 3'

The results were confirmed via Southern blotting. Two different fragments of 2874 (wild-type allele) and 3224 (disrupted allele) bp long respectively were visualized as such. Genomic DNA (see above) was prepared from all 14 transformants and after digestion with *EcoRI*, separated on a 1% agarose gel and blotted onto nylon membranes (Amersham Pharmacia biotech). The membrane was hybridised with a P³²-labelled 579 bp probe containing the 3' flanking site of *CaTPS2*, prepared by digesting pUC19/*CaTPS2* with *HindIII* and *SnaBI*. P³² labelling, via [α-³²P]dATP, was done by using the HighPrime DNA labelling kit (Boehringer, Roche Molecular biochemicals, Cat No. 1 585 584). The molecular weight marker is marker VII from Boehringer (Cat No. 1 209 264). All steps involved with Southern hybridization and hybridization conditions therefore were performed according to standard protocols (for references see above). Visualization was performed via a Phospho Imager from Fuji (BAS-1000; Software, PCBAS 2.0).

It will be readily understood that radiolabelled probes as well as nonisotopic probes can be used in Southern blotting and that detection methods will vary in accordance with the type of probes used. Biotin and digoxigenin are the nonisotopic labels that are used most frequently (Ausubel et al (1999) in "Short Protocols in Molecular Biology, 4th ed. John Wiley & Sons, New York", and units 2.9A, 2.10, 3.18-19 in particular).

5. Generation and characterisation of a homozygous *C. albicans tps2Δtps2Δ* strain

To knockout the second allele, the heterozygous *TPS2/tps2 URA3⁺* strain is first plated on 5-fluoroacetic acid (5-FOA) medium (FOA medium, Ausubel et al (1999) in "Short Protocols in Molecular Biology, 4th ed. John Wiley & Sons, New York", and units 13.1 and 13.10 in particular) to generate a *URA3⁻* strain. *URA3⁺* strains cannot survive on media containing the pyrimidine analog 5-FOA (5-FOA selection, modified method of Boeke et al (1984), Mol. Gen. Genet. 197: 345-346; uridine is used instead of uracil). Consequently, one can select for strains that have lost the *URA3* gene via homologous recombination. Loss of the *URA3* marker via homologous recombination is facilitated due to the presence of two identical *HisG* sequences flanking the *URA3* gene in the *URA3* blaster cassette.

The FOA⁺ura⁻ heterozygous clone, was transformed (LiAc method, see above) with the *TPS2* deletion construct (*URA3* disruption cassette) in order to obtain a homozygous deletion strain. After several rounds of transformation and checking by PCR, one transformant was found that did not show the band corresponding to the wild-type allele anymore in the PCR test. For this PCR analysis, the Diag3 (3' diag, see above) and Diag5 (5' diag) primers (Pharmacia) were used:

Diag5 : 5' ACCGTCGTGCTGATCCTG 3'.

The 18 bp oligonucleotide Diag5 primer is located in the open reading frame of the *TPS2* gene. For the PCR analysis with DNA isolated from 4 positive colonies, a mixture of the three following primers: Diag3, DiagHIS4 and Diag5 was used in the analysis. The molecular weight marker was the Smart ladder of Eurogentec (Cat No.: MW-1700-10). The presence of only a 1100 bp fragment indicated that in the corresponding transformant the two *TPS2* alleles were deleted. This was confirmed by Southern analysis, using the same P³²-labelled probe and marker, cutting the DNA with the same

restriction enzymes as before. Once more, all steps involved with Southern hybridization and visualization of the results were performed according to standard protocols (for references see above). The upper bands in the blot are probably due to incomplete digestion of the DNA. Further evidence for a double knock out was provided by
5 repeating the Southern blot but using a P^{32} -labelled *TPS2* specific probe. The probe consisted of a P^{32} -labelled 548 bp *NdeI*-*BamHI* fragment of the *CaTPS2* coding region. Labelling and hybridization were performed under the same conditions as defined above. The *TPS2* specific probe did not hybridise to any DNA fragment from the double deletion mutant.

10

EXPERIMENTAL

SACCHAROMYCES CEREVISIAE

Sensitivity of the *S. cerevisiae tps2Δ* strain towards antifungals

Sensitivity towards the antifungals itraconazole and ketoconazole was tested in
15 microtiter wells using a bioscreen C apparatus (Life sciences, Labsystems) and on solid culture media.

S. cerevisiae cells were pre-grown in YPglucose medium till stationary phase. The cells were diluted to a initial optical density of 0.05 OD and 300 μ l of cell suspension was added to each well of a microtiter plate. Three μ l of the correct stock
20 solution of the compound, dissolved in DMSO, were added to each well. For the control reactions, only DMSO was added. The microtiter plates were placed in the bioscreen C apparatus and were incubated at 33°C or 37°C, with medium intensity shaking (30 seconds shaking per minute). The optical density at 600 nm was measured every 30 min.

The experiments proved to be reproducible if the strains are pre-grown and
25 collected at the stationary phase. During the exponential growth phase on glucose medium, no trehalose synthesis occurs and hence no trehalose-6-phosphate is accumulated and hence the antifungals have similar effects on the *tps2Δ* strain as on the wild-type (not shown).

At 37°C, the growth of the *tps2Δ* mutant strain PVD23 in the presence of 10^{-5} to
30 10^{-8} M Itraconazole or 10^{-5} to 10^{-8} M Ketoconazole was compared to the growth of strain PVD32 and to the growth of both strains in the absence of antifungal agents, as shown in Figure 2. At this temperature the *tps2Δ* strain is already affected by itself for growth on

the glucose medium (YPD + DMSO).

The effect of the addition of 10^{-7} M Itraconazole and 10^{-6} Ketoconazole on the growth curve of prototrophic *tps2Δ* strain PVD32 and wild-type strain PVD23 at 33°C is shown in Figures 3 and 4 respectively.

5 Addition of 10^{-7} M Itraconazole or 10^{-6} M ketoconazole to the *tps2Δ* strains had a dramatic effect on their growth, with no detectable growth occurring after 24 hours. The effect of different concentrations of itraconazole on the growth at 33°C of the diploid wild-type strain (PVD190) and the diploid heterozygous *tps2Δ* strain PVD191 was tested and the results are presented in Figure 5.

10

The effect of Itraconazole on the growth of *Saccharomyces cerevisiae* wild-type (PVD32) and *tps2Δ* (PVD23) strains using YPD plates containing this compound was tested and the results are presented in Figure 6. Cells were pregrown on YPDglucose medium till stationary phase. The cells were diluted to an initial OD of 0.5. This
15 corresponds to approximately 10^7 cells/ml. Starting from this initial cell suspension, 10-fold serial dilutions were made and from each dilution 10 µl suspension was spotted on YPD plates containing different concentrations of Itraconazole. The plates were incubated at 33°C and the occurrence of growth was estimated after 1 and 2 days.

At 33°C and 10^{-7} M Itraconazole incorporated in the medium, the *tps2Δ* strain
20 was inhibited for growth, even after two days incubation, thus confirming the results obtained with the liquid media.

The *S. cerevisiae* TPS2 deletion strain is sensitive to osmotic and heat stress.

The growth characteristics of wild-type (PVD32) and *tps2Δ* (PVD23) *S. cerevisiae* strains were tested in the presence of either 1.5 M sorbitol or 5% NaCl. The
25 strains were pre-grown on YPD plates to stationary phase. The cells were diluted to an OD of 0.5. This corresponds to approximately 10^7 cells/ml Starting from this initial cell suspension, 10-fold serial dilutions were made and from each dilution 10 µl suspension was spotted on YPD plates containing either 1.5 M sorbitol or 5% NaCl. Plates of the
30 different media were inoculated with 5 µl of 10-fold serial dilutions and incubated at 30 °C.

The effect of heat stress on the prototrophic wild-type and *tps2Δ* strains was tested by inoculating YPD plates with 10 μl of cell suspension and incubating the plates at 37°C, 39°C and 41°C. Visual readings were done after 24 and 48 hours.

Figure 7 shows the effect of the osmotic and heat stress on the growth of the tested strains. The results clearly show that a *tps2Δ* strain is more sensitive to osmotic or salt stress in comparison with a wild-type strain.

A heat stress experiment has been repeated where the yeast cells were incubated at 39°C. A *tps2Δ* strain cannot grow at this temperature, whereas a wild-type strain grows perfectly well. Remarkable was the fact that the *tps2Δ* strain in the W303.1A background did not show any growth defect on plates at 37°C. In liquid media, however, there is a difference in growth rate between the wild-type and the mutant. At 41°C, none of the strains grew.

CANDIDA ALBICANS

A *Candida albicans* sequence homologous to the *Saccharomyces cerevisiae* *TPS2* gene (*Candida albicans* database, <http://www-sequence.stanford.edu/group/candida>) (Figure 8) was isolated from a *Candida albicans* wild-type strain SC5314. PCR amplification with the designed primers (REV2 and FOR2) yielded a fragment of 3171 bp long, which contains apart from the *TPS2* reading frame an additional 523 bp upstream and 639 bp downstream sequences. Figure 9 shows the genomic organisation of the *CaTPS2* gene and its flanking sites with indication of the relevant restriction sites and with indication of the two primers used to amplify the gene (REV2 and FOR2). The diagnostic primers (3' diag and 5' diag) are diagnostic primers used to check for deletions in the strain.

The cloning strategy used to obtain a heterozygous *C. albicans* disruption construct, with which competent CAI4 cells were transformed (modified LiAc method according to Sanglard et al, see above) is summarized in Figure 10. PCR analysis with a Diag3 (3' diag) 19 bp oligonucleotide primer (Pharmacia), annealing to the flanking sites of the *CaTPS2* gene outside of the fragment that has been used for the disruption, and with DiagHIS4 (Pharmacia), a 18 bp oligonucleotide primer annealing to a nucleotide sequence in the *HisG* sequence was used to verify the deletion of one of the *TPS2* alleles.

The results were confirmed via Southern blotting (Figure 11), showing two different fragments of 2874 (wild-type allele) and 3224 (disrupted allele) bp long respectively.

To knockout the second allele, the heterozygous *TPS2/tps2Δ URA3⁺* strain is first plated on 5-fluoroacetic acid (5-FOA) medium, to select subsequently for strains that have lost the *URA3* gene via homologous recombination (*URA3⁻* strains). Loss of the *URA3* marker via homologous recombination is facilitated due to the presence of two identical *HisG* sequences flanking the *URA3* gene in the *URA3* blaster cassette.

The FOA⁺ura⁻ heterozygous clone, was then transformed with the *TPS2* deletion construct in order to obtain a homozygous deletion strain. After several rounds of transformation and checking by PCR, one transformant was found that did not show the band corresponding to the wild-type allele anymore in the PCR test. For this PCR analysis, the Diag3 (3' diag, see above) and Diag5 (5' diag) primers were used. Figure 12A shows the result of the PCR analysis on DNA isolated from 4 positive colonies. A mixture of the three following primers: Diag3, DiagHIS4 and Diag5 was used in the analysis. Wild-type alleles should give a fragment of 1544 bp, whereas deletion alleles should give a fragment of 1100 bp. The presence of only a 1100 bp fragment, indicates that in the corresponding transformant the two *TPS2* alleles are deleted (lane 2 in Figure 12A). This was confirmed by Southern analysis (lane 9 in Figure 12B). The upper bands in the blot are probably due to incomplete digestion of the DNA. Further evidence for a double knock out was provided by repeating the Southern blot but using a *TPS2* specific probe. This probe did not hybridise to any DNA fragment from the transformant corresponding to lane 9 (data not shown).

A *Candida albicans* TPP activity (as measured via the method of Bencini, see above) as low as 6.9 nKat/g protein for the *tps2Δ/tps2Δ* compared to values of 231.3 for the wild-type (*TPS2/TPS2*) and 147.3 for the heterozygous knock out strain (*TPS2/tps2Δ*), provided a third proof for the double knock out in *tps2Δ/tps2Δ*. Thus, whereas in the heterozygous strain there is still approximately half the TPP activity of that found in the wild-type strain, in the putative double deletion strain there is no TPP activity at all any more. Because of this reason, the cells are no longer able to convert trehalose-6-phosphate into trehalose under conditions where normal cells would accumulate large quantities of trehalose. It is assumed that accumulation of large quantities of trehalose-6-

phosphate under these conditions is highly toxic to the cells. Trehalose-6-phosphate is a strong acid and will therefore cause intracellular acidification, which will negatively influence cellular metabolism or growth or even inhibit growth of double deletion yeast strains. Hyperaccumulation of trehalose-6-phosphate also sequesters free
5 orthophosphate (Pi) and in this way will negatively influence glycolytic flux and energy (ATP) generation. As such, total cellular energy metabolism can be severely disturbed.

Growth curves were established for *Candida albicans* cells grown in microtiter plates in YPglucose (A) and YPgalactose (B) medium. Plates were incubated in a
10 bioscreen C apparatus (Life sciences, Labsystems) at temperatures of 41°C, resulting in the accumulation of trehalose in yeasts at least in wild-type cells. The *C. albicans* strains tested in accordance with the particular embodiment were the *TPS2/TPS2* SC5314 wild-type strain, the heterozygous *TPS2/tps2Δ* strain (CC5) and the homozygous *tps2Δ/tps2Δ* strain (CC17).

15 These growth curves at 41°C already showed that there is a clear extension of the lag phase and a clear inhibitory effect on the growth rate when respectively one or two of the alleles of the *TPS2* gene are deleted and especially when the two *TPS2* alleles are deleted. Such growth curves provide proof of principle for the fact that as a result of *TPS2* knock out, accumulation of trehalose-6-phosphate in cells, cytotoxic to at least
20 yeast cells in higher concentrations, can hamper or even inhibit cell growth.

At 43°C, the effect was even more pronounced. At this particular temperature, the wild-type *Candida albicans* still grew quite well, whereas heterozygous and especially homozygous deletion of *TPS2* resulted in a dramatic drop in growth rate, presumably as a result of accumulation of trehalose-6-phosphate in the cells. This was observed both for
25 galactose (YPgalactose) and glucose (YPglucose) medium (Figures 13 A and B).

SCREENING ASSAY

Several known inhibitors of different phosphatase enzymes have been tested, such as vanadate, tetramisole, (-)-p-bromotetramisole, (+)-p-bromotetramisole, levamisole, N-
30 ethylmaleimide (NEM) and Dithiodinitrobenzoate (DTNB) for their inhibitory effect on TPP activity.

To perform a screening assay with the different candidate inhibitory compounds, *Saccharomyces cerevisiae* strain PVD45 (PVD45: a *leu2-3/112ura3-1 trp1-1 his3-11/15*

ade2-1 can1-100GAL SUC2 tps1Δ::TRP1 tps2Δ::LEU2 + pSAL4/TP2S (URA3)) was used which over-expresses *TPS2* from *S. cerevisiae*.

The screening assay comprises the following steps:

5

1. Preparation of the extracts.

The *S. cerevisiae* strain PVD45 was grown in 50 ml SDgal-ura medium to stationary phase. Extracts were prepared according to the protocol described previously (see
10 preparation of the extracts).

2. Screening of the candidate inhibitory compounds NEM and DTNB.

Stock solutions of 100 mM N-ethylmaleimide (NEM) and 100 mM
Dithiodinitrobenzoate (DTNB) are prepared in water and ethanol respectively.
15 From these stock solutions, serial dilutions of 0.1 mM, 1mM and 10 mM, are
made. For the experiments 56 µl of each dilution of the compound is added to the
Assay I solution consisting of 40 µl of 200 mM Tricine buffer (pH7), 20 µl of 0.1
M MgCl₂, 20 µl trehalose-6-phosphate (Sigma) and 68 µl H₂O (mix1, see above).
For the Assay I control mixture 20 µl trehalose-6-phosphate is omitted and
20 replaced by 20 µl H₂O. Thus in the experiments the following final
concentrations of the tested compounds NEM and DTNB were used: 35 mM, 3.5
mM, 0.35 mM, 35 µM and 0 µM (= control).

To the assay mixture 20 µl of extract is added.

The assay mixtures and the control mixtures are incubated for 30 min at 30°C;
25 subsequently boiled for 5 min to stop the reaction and cooled down to room
temperature. The micro-centrifuge tubes were centrifuged for 5 min at 14000
rpm.

Measurement of the trehalose-6-phosphate activity is performed according to the
methods described previously. The chemical test, based on the method of Bencini
30 (1983), might be preferred over the enzymatic test (EnzChek™) since it is linear
over a broad range of concentrations and is less prone to interference and the
generation of false positives compared to the enzymatic test.

The marked inhibition of trehalose-6-phosphate phosphatase activity in *S.*

cerevisiae strain PVD45 by NEM and DTNB is shown in Figures 14 and 15. Bencini's method for the measurement of free orthophosphate, clearly demonstrated an inhibitory effect of NEM and DTNB at 10^{-4} and 10^{-5} M, whereas at these concentrations none of the following compounds inhibited TPP activity: vanadate, tetramisole, (-)-p-bromotetramisole, (+)-p-bromotetramisole, levamisole, chlorogenic acid. The above mentioned selective and specific inhibitory action of NEM and DTNB whereas general phosphatase inhibitors had no inhibitory effect on trehalose-6-phosphate phosphatase were the first indication that specific inhibitors can be found for TPP activity which will not interfere with phosphatase enzymes of host cells.

Assays as described above for a limited set of test compounds, were performed in micro-centrifuge tubes. An assay in accordance with the present invention further involves screening test inhibitory compounds from large libraries of synthetic or natural compounds. Synthetic compound libraries are commercially available from, for example, Maybridge Chemical Co. (Trevillet, Cornwall, UK), Comgenex (Princeton, NJ), Brandon Associates (Merrimack, NH), and Microsource (New Milford, CT), Chembridge Corporation (San Diego, CA). A rare chemical library is available from Aldrich Chemical Company, Inc. (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available from, for example, New Chemical Entities, Pan Laboratories, Bothell, WA or MycoSearch (NC), Chiron, or are readily producible. Plant extracts may also be obtained from the University of Ghent, Belgium. Additionally, natural and synthetically produced libraries and compounds are readily modified through conventional chemical, physical, and biochemical means. Performing the screening assays in microtiter plates, for instance 96-well microtiter plates, allows screening by an automated robotic system and as such the testing of large numbers of test samples within a reasonable short time frame. The above list of commercial libraries is non-exhaustive.

In addition, preferably the TPP inhibitors will not interfere with any essential metabolic process or pathway of the human, animal or plant in need of treatment. In the context of the present invention, a 5,000 compounds-collection (DIVERSet™) from Chembridge Corporation (San Diego, CA) was screened for identifying novel TPP-specific intracellular inhibitors in accordance with the present invention. DIVERSet™ is a unique set of drug-like, hand-synthesized small molecules, rationally preselected to form a "universal" library that covers the maximum pharmacophore diversity with the

minimum number of compounds. As appreciated by those skilled in the art, other libraries such as those previously mentioned in the non-exhaustive list above, may be screened. Such screening may yield inhibitors, other than the ones explicitly disclosed in the present invention but falling within the scope of the present invention, inclusive
5 further screening with structure analogs.

Details on the large scale screening assay

DIVERSet™ compounds are delivered in 96-well microtiter plates each containing 80 compounds, with each compound representing about 0.1 mg of lyophilized
10 material. In the context of the present invention, the compounds were dissolved in 33 μ l of DMSO resulting in a mean concentration of 10^{-2} M. From these stock plates (Figure 17), 10^{-3} M working plates were then prepared via a 10-fold dilution in DMSO (total volume per well is 50 μ l) (Working plates). Next, 2 μ l of each well of the working plates was transferred to the corresponding well of a fresh microtiter plate, to which 148 μ l of
15 mix1 (see above) was added. For the controls, the 2 μ l of test compound at 10^{-3} M were replaced by 2 μ l pure DMSO (negative control) or 2 μ l of a 10^{-3} M DTNB solution in DMSO (positive control) respectively. To each well 10 μ l of a yeast extract with final protein concentration of about 10 mg/ml (for the large scale extraction procedure and measurement of total protein content see above) was then added, whereafter the plates
20 were incubated for 30 minutes at 30°C in a standard incubator in the dark. Next, 15 μ l of each well was transferred to the corresponding well of a fresh microtiter plate, to which 148 μ l of the aqueous mixture at pH 5 of ammonium molybdate (100 mM) and Zinc acetate mixture (15 mM) and 37 μ l of a 10% aqueous ascorbic acid solution (pH5) (see above) were added. Well A to F of the first column of each microtiter plate contained an
25 orthophosphate (Pi) standard series (0, 0.02, 0.1, 0.2, 1 and 5mM in H₂O). 15 μ l of the Pi standard series hereby replaced the otherwise 15 μ l of test compound plus mix1 plus yeast extract. Screening of the test plates was performed after 20 minutes of incubation at 30°C in the Biomek robotic system, by measuring the optical density at 750 nm (OD₇₅₀) using a SPECTRAMAX spectrophotometer. Potential TPP inhibitors were in a second
30 round of screening retested at 4 differential concentrations of 10^{-5} , 10^{-6} , 10^{-7} and 10^{-8} M in DMSO respectively.

The strain that was used to prepare the extracts for the large-scale screening assay

in accordance with this particular embodiment of the present invention, is a *Saccharomyces cerevisiae* wild-type strain (W303.1 A) in which the yeast *TPS2* gene is overexpressed. FPLC fractions (750 μ l fractions of a superdex200 column (Amersham Pharmacia biotech)) containing TPP activity (fractions 11-13) were pooled, concentrated on VTVASPIN columns (VIVAscience) by a 30 min centrifugation step at 3500 rpm and used for screening in the assay. The final protein concentration of the extract used for screening was about 10 mg/ml.

The screening assay for determination of inhibitors of TPP activity in microtiter plates is adaptable for automation and as such allows high throughput screening. In the framework of the present invention, the Biomek robotic system was applied. It will be understood by a person known in the art that equivalent automated screening methods could be used as well.

The first round of screening resulted in 86 compounds with TPP inhibitory actions similar to or better than that of 10^{-5} M DTNB ("good" TPP inhibition). These compounds with their respective numbers/positions in the DIVERSet™ compound library are shown in Table 1. Subsequently, these 86 compounds were tested again, but this time at concentrations of 10^{-5} , 10^{-6} , 10^{-7} and 10^{-8} M respectively in DMSO. As such, 5 compounds with good TPP inhibition activity could be identified. These compounds (113596, 113610, 133207, 136794 and 143067) are indicated in bold italic and marked with an asterisk in Table 1.

Table 1: Indication of number and position (plate number – position in the plate) of compounds identified in the DIVERSet™ library as being compounds with good TPP inhibition activity

Compound Number	Position	Compound Number	Position
♦100764	♦PL 2 – D 4	155043	PL 41 – G 8
112710	PL 11 – H 4	155137	PL 41 – G 10
114854	PL 13 – A 10	153298	PL 42 – G 4
115308	PL 13 – D 7	156323	PL 44 – A 11
115800	PL 14 – A 2	158594	PL 44 – B 6
115806	PL 14 – A 5	159194	PL 46 – A 7
117003	PL 14 – F 6	159195	PL 46 – B 7

117033	PL 14 - G 6	159189	PL 46 - C 6
121911	PL 16 - H 2	156457	PL 46 - D 5
<i>*136794</i>	<i>*PL 21 - H 5</i>	156643	PL 46 - G 4
<i>*143067</i>	<i>*PL 23 - A 9</i>	159193	PL 46 - G 6
150050	PL 23 - H 2	157408	PL 46 - H 7
102330	PL 25 - A 3	140894	PL 46 - H 8
102341	PL 25 - A 7	155270	PL 46 - H 10
105299	PL 27 - E 9	156945	PL 47 - B 4
105463	PL 27 - G 10	106160	PL 47 - B 7
111087	PL 30 - A 2	122621	PL 47 - C 11
111189	PL 30 - A 8	155044	PL 47 - F 4
115781	PL 31 - A 8	159239	PL 47 - G 5
116321	PL 31 - B 7	161339	PL 47 - G 8
128067	PL 33 - G 8	105553	PL 47 - H 7
135235	PL 34 - G 10	108489	PL 47 - H 10
142159	PL 35 - A 5	104499	PL 48 - G 5
144152	PL 35 - B 5	169111	PL 49 - H 8
141531	PL 35 - C 3	182557	PL 51 - F 6
143530	PL 35 - C 5	<i>♦*113596</i>	<i>♦*PL52-D3</i>
141882	PL 35 - C 10	<i>♦*133207</i>	<i>♦*PL 52 - E 10</i>
143736	PL 35 - D 5	216645	PL 54 - H 4
136265	PL 35 - D 6	218940	PL 56 - A 2
142389	PL 35 - D 7	217973	PL 57 - H 4
136286	PL 35 - G 3	147933	PL 60 - A 4
141951	PL 35 - H 9	152078	PL 60 - E 9
143463	PL 36 - D 6	215222	PL 61 - C 10
143092	PL 36 - F 6	217342	PL 61 - F 10
143462	PL 36 - H 6	133445	PL 62 - E 7
104966	PL 38 - B 5	117172	PL 62 - F 5
118196	PL 38 - G 3	<i>♦133805</i>	<i>♦PL 62 - G 7</i>
107036	PL 38 - G 8	<i>♦*113610</i>	<i>♦*PL 63 - A 8</i>
150049	PL 41 - D 6	113222	PL 63 - B 3
153960	PL 41 - D 8	113233	PL 63 - C 3
145704	PL 41 - E 7	175327	PL 63 - F 6

146000	PL 41 - F 7	151234	PL 63 - H 3
151547	PL 41 - G 3		
146002	PL 41 - G 7		

DIVERSet™ compounds 136794 and 143067 (for their structures, see Figure 17), were applied in 7 different concentrations (0, 1×10^{-7} , 3×10^{-7} , 1×10^{-6} , 3×10^{-6} , 1×10^{-5} and 3×10^{-5} M in DMSO respectively) to *S. cerevisiae* and from their inhibitory activity the IC₅₀ calculated. Three DIVERSet™ compounds without any TPP inhibitory activity (109146, 116321 and 145704) and DNTB were included as respectively negative and positive controls (Figure 18). DIVERSet™ compound 136794, comparable in its TPP inhibiting action to DNTB at 10^{-5} M, is less active at lower concentrations. The calculated IC₅₀ for this compound is 1.5×10^{-5} M. DIVERSet™ compound 143067, has a calculated IC₅₀ of 3.1×10^{-7} M under the given test conditions and in accordance with this particular embodiment of the present invention. Compound 143067 has the strongest TPP inhibitory potential at 10^{-7} M. The drop in activity at higher concentrations is most probably due to a bad solubility of this compound at high concentrations .

The inability to penetrate the cell (non-permeability), rapid degradation of a compound or a conversion to inactive forms once inside the cell are possible reasons for a compound to be non-active *in vivo*. Therefore, next to the *in vitro* tests described above, the activity of some of the selected compounds on the growth of the yeast *Saccharomyces cerevisiae* wild-type strains (*in vivo* screening) and was tested using the bioscreen C apparatus (Life sciences, Labsystems). This system allows to follow the effect of the compounds on up to 200 different cultures simultaneously. In Figures 19 A and B, the results are given for the effect of DIVERSet™ compounds 136794 and 143067 on the growth of a wild-type *S. cerevisiae* strain (W303.1A) grown in YPD (YPglucose) at 37°C, a temperature at which the yeast accumulates trehalose through the action of TPS and TPP enzymes. Other incubation conditions in the bioscreen C apparatus were as described above. The *in vivo* results confirmed the *in vitro* data and even the concentrations at which the DIVERSet™ compounds 136794 and 143067 are most inhibitory to TPP.

The 86 DIVERSet™ compounds with good TPP inhibitory activity, identified via the screening method of the present invention (see above) were also tested on *Candida albicans* cells (whole-cell assay). *In vivo* inhibition tests with the TPS2/TPS2 *C. albicans*

wild-type strain (SC5314), grown on YPglucose medium at 43°C, identified DIVERSet™ compounds 133207, 133805 and 133610 (indicated in bold italic and marked by a diamond in Table 1) as the strongest inhibitors under the given test conditions (10^{-5} and 10^{-7} M in DMSO). Control compounds were DTNB and NEM (positive controls) and DMSO (negative control). The results are summarized in Figures 20 A and B.

To check for specificity, the inhibitory effect of the 3 DIVERSet™ compounds 133207, 133805 and 133610 was tested on the *C. albicans tps2Δ/tps2Δ* strain. This strain was grown at 39°C instead of at 43°C, since at the latter temperature the strain is not growing so well (see above). Since the Tps2 (TPP) enzyme is absent in the *tps2Δ/tps2Δ* strain (double deletion mutant), one should not see an inhibitory effect or only a minor effect of the compounds, as demonstrated in Figures 21 A and B. Test compounds were added at concentration of 10^{-5} (A) and 10^{-7} M (B) in DMSO. Controls were the same as for the wild-type strain.

The 3 aforementioned compounds proved to be specific inhibitors of TPP as the compounds do not or only slightly affect the growth of the double deletion mutant. DIVERSet™ compounds nr 133207 and 113610 have a strong effect on the growth rate of the wild-type *Candida albicans* strain, whereas compound 133805 is less effective for growth inhibition with wild-type *Candida albicans*. Remarkably, in the presence of the latter compound the cells grow a little slower in the beginning but after some hours cells stop growing completely. Since there was no effect at all of this compound in the *tps2Δ/tps2Δ* background, this might indicate that it also acts on Tps2 (TPP). In addition to compounds nr 133207 and 113610 there was a third DIVERSet™ compound with a strong inhibitory effect on the growth rate of *Candida* cells, namely compound nr 113596. The presence of DTNB did not seem to have an effect on the growth of wild-type *Candida* cells under the given conditions. Addition of NEM caused a slight reduction in the growth rate. The inhibitors identified in accordance with the present invention are thus superior in their TPP-specific inhibitory activity to NEM and DTNB at 10^{-5} M, especially *in vivo*.

The two compounds causing strong growth inhibition in *Saccharomyces cerevisiae*, DIVERSet™ compounds 136794 and 143067, were also tested on *Candida albicans*. The compounds were tested at 10^{-7} M only, since at 10^{-5} M compound 143067

was less inhibitory in *Saccharomyces cerevisiae* (see above). Also in *Candida albicans* this compound caused significant growth inhibition at 10^{-7} M in DMSO. The inhibition is as strong as with DIVERSet™ compound 113610 (positive control). Another compound, with comparable activity was identified, namely compound nr 100764 (for structure, see Figure 17). Figure 22 shows the compound's behaviour compared to compounds nr 136794, 143067 and 113610 (positive controls) and DMSO (negative control). Growth curves were established for a wild-type *C. albicans* strain (SC5314), grown at 43°C on YPD medium in the presence of 10^{-7} M of the test compounds.

The present invention further includes a method for treating fungal infection in a patient in need of such treatment, comprising administering to said patient an antifungal agent identified according to the above assay method or a pharmaceutically acceptable salt, ester or pro-drug thereof.

More generally, the invention includes a method for treating a fungal, a bacterial or a protozoal infection, or a nematode, an insect, worm or mite infestation, in a human, animal or a plant in need of such treatment which comprises administering a specific inhibitor which inhibits a fungal enzyme converting with a low or high degree of specificity a sugar phosphate into a sugar or a sugar alcohol phosphate into a sugar alcohol that are accumulated in large quantities by cells for instance, but not exclusively, under conditions deviating from the optimal growth condition or as a reaction to stress conditions, the inhibition being either directly of the enzyme or indirectly, e.g. by suppressing the expression of the corresponding gene. The inhibitor may be determined by the assays described above.

Compositions in accordance with the present invention include a biologically or therapeutically effective amount of an inhibitory agent (either biocide or pharmaceutical) determined in accordance with a screening assay in accordance with the present invention. Therapeutically or biologically effective amounts are those quantities of the active agent of the present invention that afford prophylactic protection against the relevant infections or infestations in humans, animals or plants, and which result in amelioration or cure of an existing infection or infestation in humans, animals or plants.

The biologically or therapeutically active agents or compositions can be formed into dosage unit forms, such as for example, creams, ointments, lotions, powders, liquids, tablets, capsules, suppositories, sprays, or the like. If the antifungal composition is formulated into a dosage unit form, the dosage unit form may contain an antifungal

effective amount of active agent.

The active agents and compositions of the present invention are useful for preventing or treating fungal infections in humans, animals or plants. Fungal infection prevention methods incorporate a prophylactically effective amount of an antifungal agent or composition. A prophylactically effective amount is an amount effective to prevent fungal infection and will depend upon the fungus, the agent and the host. These amounts can be determined experimentally by methods known in the art. Fungal infection treatment methods incorporate a therapeutically effective amount of an antifungal agent or composition. A therapeutically effective amount is an amount sufficient to stabilize or to ameliorate a fungal infection.

The prophylactically and/or therapeutically effective amounts can be administered in one administration or over repeated administrations. Therapeutic administration can be followed by prophylactic administration, once the initial fungal infection has been resolved.

The antifungal agents and compositions can be applied to plants topically or non-topically, i.e., systemically. Topical application is preferably by spraying onto the plant. Systemic administration is preferably by application to the soil and subsequent absorption by the roots of the plant.

The antifungal agents and compositions can be administered to animals topically or systemically.

Although the invention is described in detail with reference to specific embodiments thereof, it will be understood that variations which are functionally equivalent are within the scope of this invention. Such modifications are intended to fall within the scope of the appended claims. It will be understood that structural analogs of the compounds or substances disclosed in the present invention fall under the scope of it.

Various publications are cited herein, the disclosure of which are incorporated by reference in their entireties.

CLAIMS

1. A test method for assessing the activity of candidate substances as inhibitors of a first cell enzyme converting a sugar phosphate into a sugar or a sugar alcohol phosphate into a sugar alcohol in cells, the sugar or sugar alcohol being accumulated in large quantities by the cells for instance, but not exclusively, under conditions deviating from the optimal growth condition of the target cells or as a reaction to stress conditions, the inhibition being either directly of the first enzyme or indirectly; the method comprising the steps of:
Step 1: contacting a candidate inhibitor with a biological medium comprising the sugar phosphate or sugar alcohol phosphate and the first enzyme;
Step 2: measuring activity in the medium which depends upon the activity of the first enzyme;
Step 3: repeating steps one and two with further candidate inhibitors; and
Step 4: selecting at least one candidate inhibitor which reduces activity of the enzyme compared with the same medium without the inhibitor under the same conditions.
2. The test method of claim 1, wherein the enzyme inhibition slows down or impairs specifically the growth of the target organism, at least under stress conditions.
3. The method according to claims 1 or 2, wherein the first cell enzyme is a phosphatase which synthesizes a sugar or sugar alcohol as a reaction to stress.
4. The method according to claims 1 to 3, wherein the reduction in activity is preferably at least 25%, more preferably at least 50%, more preferably at least 75%, more preferably at least 85% and most preferably at least 95%.
5. The method according to any previous claim, further comprising the steps of:
step 5: assessing the activity of a second cell enzyme which is involved in the synthesis of the corresponding sugar phosphate or sugar alcohol phosphate; and the selecting step includes selection of inhibitors which reduce the activity of the first enzyme while maintaining a viable activity of the second enzyme.
6. The method according to claim 5, wherein a viable activity of the second enzyme is at

least 25%, more preferably at least 50% and most preferably at least 75% of the activity of the second enzyme in the same medium under the same conditions but without the inhibitor.

5 7. The method according to any previous claim, wherein the medium includes sub-cellular organelles or sub-cellular non-organelle components, a cell culture, or animal tissue, or an animal.

8. The method according to claim 7, wherein the sub-cellular organelles or sub-cellular
10 non-organelle components or the cell culture are obtained from cells from an insect or a nematode or a fungus or a bacterium or a protozoa or a worm or a mite or any other organism expressing the first enzyme of any of the previous claims.

9. The method according to claim 7, wherein the medium is a cell culture and the first
15 enzyme is an intracellular enzyme.

10. The method according to any previous claim wherein the first enzyme is an enzyme controlling a metabolic pathway which has an intermediary compound which is normally produced as a reaction to stress conditions and which is toxic to the cell.

20

11. The method according to claim 10, wherein the first enzyme is one of trehalose-6-phosphatase, glycerol-3-phosphatase, mannitol-1-phosphatase, sorbitol-6-phosphatase, arabitol-5-phosphatase, and erythritol-4-phosphatase.

25 12. The method according to any previous claim, wherein steps 1 is carried out with the first enzyme *in vitro*, further comprising the steps after step 4 of:

contacting the candidate inhibitors selected in step 4 with a biological medium comprising whole cells having the first enzyme as an intracellular enzyme; and selecting those candidate inhibitors which reduce the growth of the cells.

30

13. The method according to any previous claim, further comprising the step of: using a selected inhibitor in a pharmaceutical preparation or a biocide.


14. An inhibitor obtained by the method of any of the claims 1 to 11.

15. An inhibitor obtainable by the method of any of the claims 1 to 11, the inhibitor inhibiting in cells a cell enzyme converting a sugar phosphate into a sugar or a sugar alcohol phosphate into a sugar alcohol, the sugar or sugar alcohol being accumulated in large quantities by the cells for instance, but not exclusively, under conditions deviating from the optimal growth condition of the cells or as a reaction to stress conditions, the inhibition being either directly of the first enzyme or indirectly.


16. An inhibitor according to claims 14 or 15, wherein the inhibitor is an intracellular inhibitor

17. An inhibitor according to any of claims 14 to 16, wherein the inhibitor specifically inhibits TPP enzymatic activity

18. An inhibitor according to any of claims 14 to 17, whereby the inhibitor is a substance with the structure formula:




19. An inhibitor according to any of claims 14 to 17, whereby the inhibitor is a substance with the structure formula:



4

20. An inhibitor according to any of claims 14 to 17, whereby the inhibitor is a substance with the structure formula:


5



10


21. An inhibitor according to any of claims 14 to 17, whereby the inhibitor is a substance with the structure formula:

15



20


22. An inhibitor according to any of claims 14 to 17, whereby the inhibitor is a substance with the structure formula:



25


23. An inhibitor according to any of claims 14 to 17, whereby the inhibitor is a substance with the structure formula:

30



5

24. An inhibitor according to any of claims 14 to 17, whereby the inhibitor is a substance with the structure formula:



25. An inhibitor according to claims 14 to 17, whereby the inhibitor is any of the following substances identified in the DIVERSet™ library:

Compound Number	Position	Compound Number	Position
100764	PL 2 - D 4	155043	PL 41 - G 8
112710	PL 11 - H 4	155137	PL 41 - G 10
114854	PL 13 - A 10	153298	PL 42 - G 4
115308	PL 13 - D 7	156323	PL 44 - A 11
115800	PL 14 - A 2	158594	PL 44 - B 6
115806	PL 14 - A 5	159194	PL 46 - A 7
117003	PL 14 - F 6	159195	PL 46 - B 7
117033	PL 14 - G 6	159189	PL 46 - C 6
121911	PL 16 - H 2	156457	PL 46 - D 5
136794	PL 21 - H 5	156643	PL 46 - G 4
143067	PL 23 - A 9	159193	PL 46 - G 6
150050	PL 23 - H 2	157408	PL 46 - H 7
102330	PL 25 - A 3	140894	PL 46 - H 8
102341	PL 25 - A 7	155270	PL 46 - H 10
105299	PL 27 - E 9	156945	PL 47 - B 4
105463	PL 27 - G 10	106160	PL 47 - B 7
111087	PL 30 - A 2	122621	PL 47 - C 11
111189	PL 30 - A 8	155044	PL 47 - F 4
115781	PL 31 - A 8	159239	PL 47 - G 5
116321	PL 31 - B 7	161339	PL 47 - G 8
128067	PL 33 - G 8	105553	PL 47 - H 7
135235	PL 34 - G 10	108489	PL 47 - H 10
142159	PL 35 - A 5	104499	PL 48 - G 5

144152	PL 35 - B 5	169111	PL 49 - H 8
141531	PL 35 - C 3	182557	PL 51 - F 6
143530	PL 35 - C 5	113596	PL52-D3
141882	PL 35 - C 10	133207	PL 52 - E 10
143736	PL 35 - D 5	216645	PL 54 - H 4
136265	PL 35 - D 6	218940	PL 56 - A 2
142389	PL 35 - D 7	217973	PL 57 - H 4
136286	PL 35 - G 3	147933	PL 60 - A 4
141951	PL 35 - H 9	152078	PL 60 - E 9
143463	PL 36 - D 6	215222	PL 61 - C 10
143092	PL 36 - F 6	217342	PL 61 - F 10
143462	PL 36 - H 6	133445	PL 62 - E 7
104966	PL 38 - B 5	117172	PL 62 - F 5
118196	PL 38 - G 3	133805	PL 62 - G 7
107036	PL 38 - G 8	113610	PL 63 - A 8
150049	PL 41 - D 6	113222	PL 63 - B 3
153960	PL 41 - D 8	113233	PL 63 - C 3
145704	PL 41 - E 7	175327	PL 63 - F 6
146000	PL 41 - F 7	151234	PL 63 - H 3
151547	PL 41 - G 3		
146002	PL 41 - G 7		

26. An inhibitor according to any of claims 14 to 25, whereby the inhibitor is a biologically active salt, an ester derivative or a homolog of the compounds of claims 14
5 to 25 with the same functional activity.

27. A pharmaceutical preparation including one or more of the inhibitors of any of claims 13 to 26.

10 28. The pharmaceutical preparation according to claim 27, further comprising an antifungal drug.

29. The pharmaceutical preparation of claim 28, wherein the antifungal drug is one of

Amphotericin B, Flucytosine, Ketoconazole, Miconazole, Fluconazole, and Itraconazole.

30. A biocide acting on fungi, insects, nematodes, bacteria or other organisms accumulating large quantities of a sugar alcohol or a sugar in response to stress

5 comprising the inhibitor of claim 13 or 14.

31. The biocide of claim 30, further comprising an antifungal agent.

32. The biocide of claim 31 wherein the biocide is an azole.

10

33. A method of increasing the sugar phosphate or sugar alcohol phosphate content in a target cell having a trehalose pathway, comprising the step of:
reducing the activity of a first cell enzyme, converting a sugar phosphate into a sugar or a sugar alcohol phosphate into a sugar alcohol in cells, by using an inhibitor.

15

34. A method of increasing the sugar phosphate or sugar alcohol phosphate content in a mammalian parasite having a trehalose pathway, comprising the step of:
reducing the activity of a first cell enzyme, converting a sugar phosphate into a sugar or a sugar alcohol phosphate into a sugar alcohol in cells.

20

35. A method of increasing the sugar phosphate or sugar alcohol phosphate content in a mammalian parasite having a trehalose pathway, comprising the step of:
reducing or inhibiting the activity of a first cell enzyme, converting a sugar phosphate into a sugar or a sugar alcohol phosphate into a sugar alcohol in cells, via single or
25 double knockout deletion mutants for that enzyme.

36. A method of reducing or impairing the pathogenicity of a mammalian parasite having a trehalose pathway by promoting hyperaccumulation of a sugar phosphate or a sugar alcohol phosphate.

30



1
ABSTRACT

The use of an enzyme found in fungi, bacteria, insects, nematodes, worms, mites, protozoa
5 etc. as a target in a screening assay is described by means of which agents capable of
inhibiting the function of that enzyme may be identified. The screening assay may include
complete cell or purified-enzyme assays. In particular, the present invention relates to a
screening assay for inhibitors or suppressors of sugar alcohol phosphatases or sugar
phosphatases, and more in particular inhibitors or suppressors of trehalose-6-phosphate
10 phosphatase, as well as preparations, in particular, pharmaceutical preparations, which
include inhibitors or suppressors obtained from the screening assay.

Inhibitors are described as well as applications in biocides and antifungal pharmaceuticals.





Tps1: trehalose-6-P synthase
 Tps2: trehalose-6-P
 phosphatase




Fig. 1



*Tps1*Δ



*Tps2*Δ

Growth curves of a protrophic wt strain in the presence of different concentrations of itraconazole at 37°C




Fig. 2A

Growth curves of a protrophic *tps2Δ* strain in the presence of different concentrations of itraconazole at 37°C




Fig. 2B

Effect of 10^{-7} M Itraconazole on growth
of wt and *tps2Δ* strains




Fig. 3

Effect of 10^{-6} M ketoconazole on the growth
of wt and *tps2Δ* strains




Fig. 4

Growth curve of a diploid WT strain in the presence of different concentrations of itraconazole




Fig. 5A

Growth curve of a diploid heterozygous *tps2Δ* strain
in the presence of different concentrations of itraconazole





Fig. 5B

After 1 day incubation



There was no growth of the strains on YPD at 41°C

Fig. 7

S.cerevisiaeTPS2
C.albicans -----MTTAAQDNSPKKQRRIINCVTQLFYKIQLGESNDD----WKIS 39
MAPQQVNAFSAANGSIPSPKFEKGKGLKLSGAILNVMTSLPLQIISDYDNKTCGQYWDVE 60
... * ** : * . * . * . * . *

S.cerevisiaeTPS2
C.albicans ATTGNSALYSSLEYLQFDSTETEQHVVGWVGELRTERNLFTREAKEKFOQLDDDDPLYLT 99
TVRGNSALYSSQHFLEAEN-KEWETHLAWTGELINKKGTSSSLTADT----LQDDPLYLD 115
: . * . * . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans KEQINGLITLLODHMKSDKEAKDTTQTAPVTNNVHPVWLLRKNQSRWRNYAEKVIWPTF 159
EEDKLKTEKLCASG-----TFN---LHPVWLLRRDQGRWRKYAENVLWPFV 160
: * : . * * : * : * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans HYILNPSNEGEQEQXNWWDYVKFNEAYAKIGEVYKGD LIWIHDYILLLLPQLLRMKFN 219
HYIQGQPSDGEKAETDAWHDYVKFNEAYLNKIKSVYKPGDIWIHDYILLLLPQLLRMEFF 220
* . . . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans DESIIGYFHEAPWPSNEYFRCLPRRKQILDGLVGANRICFONESFSRHEVSSCCQLLDA 279
N--AYIGFFLHVPPSPSEYFRCLSKRSQLLDGLGADKIGFQSDSFQREFTSCCARVLGC 278
: * . * . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans TAKSKNSSSDQYQVSUYGGDVLVDSLPIGVNTTQILKDAFT--KQIDSKVLSTKQAYQ 337
EVNR--D-----SVSAYGTTISVETLPIGIDTEKISHDAFSSSELGVEEKVCALKQVYK 329
: . : * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans NKCIIGRDRRLDSVRGVVOKLRAFETFLAMYPEWRDQVVLQVSSPTANRNSPQTERLEQ 397
GKCLIVGRDRRLDKVRGVIQKLEGFEFLDMYPEWRDQVVLQVSSPGYS-HSAN---VET 385
* . * . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans QVNELVNSINSEYGNLNFSPVCHYMRIPKIVYLSLLRVADLCITSVRDGMNTTAEIV 457
RVETIISRINSKZGNLNETPVLAYQMRVAKSEYLLALLRVADLALITSVRDGMNTTSLFV 445
: * . * . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans TVKSEMSNFLCYGNPLILSEFSGSSNVLDADAIVNPNWDSVAVAKSINMALCLDKKESNL 517
ICQKYN-N-----SPLILSEFTGTATVLKADIMVNPWDSVGVARTINCLMLSTKXKVS 499
: . : * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans ESKLWKEVPTIQDWTNKLSSLXKASDDDDVERKMTPALNRPVLLNXYKQAKRRLFLFD 577
ESKLYEKVLSNTVQNWSTTFICILSHSIVTHSNSTPALNRPILLNXYKESQRRLFLFD 559
* . * . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans YDGTLTPIVKCPAAAIIPSARLYTILQKLCADPHNQIWIISGRDQKFLNKWLGGKLPQLGL 637
YDGTLTPIVQDPAAAIIPSDKLNRIILDVLSDDPKNQIWIISGRDQAFLEKWMGNKN--VGL 617
* . * . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans SAHGGCFMKDVSQDWNVLTEKVDMSWQVRVNEVMEESTTRTPGSFTERKXVALTWYRR 697
SAHGGCFMKDIGSKWVNLAASFDMWQEKVDDIFKYTEKTPGSNTERKXVALTWYRR 677
* . * . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans TVPELGZFEAKELKEKLLS-FTDDFDLEVMGKXANIEVRPRFVNKGELVKRLVWECHGK 756
ADPDLGNFQAEKCKELNDTVAKEDVEVMAGKXANIEVRPKFVNKGELVKRLVLEPEGAK 737
: * . * . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans QDMLKG--ISEKLPKDEMPDFVLCLGDDFTDEDMFRQLNTTETCNKEXTPDQKNQWGNYG 814
QEXEPTGECKTDIPTELPDFMLCLGDDLTDEDMFNSLNEINKSWKGN-RPTNKFGSYG 796
* : . . . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans FTFVTVGSASKTAKAHLTPQQVLETGLLVGDVSLFQSAGTVDLDSRGHVKNSESSL 874
VTFVAVGPASKTVALAHLNEPRQVLETGLLAGLVSI FESAGTVDLDDRVTLPVLCPLK 856
* . * . * . * . * . * . * . * . * . * . * . * . * . * . *

S.cerevisiaeTPS2
C.albicans KSKLASKAYVMKRSASTGAKV 896
DQDMLYLQYLYVKKLVKAKL 878
... : . * . *

Fig. 8




Fig. 9




Fig. 10





Fig. 4

*Fig. 1a A*




Fig. 12 B




Fig. 13 A




Fig. 13B




Fig. 14




Fig. 15










Fig. 16





Compound nr. 136794
 $C_{19}H_{14}N_2O_2$



Compound nr. 143067
 $C_{15}H_{12}Cl_3N_3O_4S$





Compound nr. 113596
 $C_{10}H_7BrCl_3NO_4$





Compound nr. 113610
 $C_{12}H_9BrCl_3NO_5$



Fig. 17



Compound nr. 133207
 $C_{14}H_9NO_2$



Compound nr. 133805
 $C_{20}H_{16}N_2O_6$



Compound nr. 100764
 $C_{36}H_{30}N_4O_4$

Fig. 17 (Continuation)




Fig. 18




Fig. 19A





Fig. 19B



Fy. 20 Δ




Fig. 20 B




Fig. 21A




Fig. 21 B




Fig. 22

